Details of the Drug

General Information of Drug (ID: DMCMBHA)

Drug Name
Erlotinib
Synonyms
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
Indication
Disease Entry ICD 11 Status REF
Adrenal gland neoplasm N.A. Approved [1]
Adult hepatocellular carcinoma N.A. Approved [1]
Brain cancer 2A00 Approved [1]
Esophageal disorder N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [2]
Pancreatic adenocarcinoma N.A. Approved [1]
Psoriasis EA90 Approved [1]
Salivary gland squamous cell carcinoma N.A. Approved [1]
Pancreatic cancer 2C10 Phase 3 [2]
Colon cancer 2B90.Z Phase 2 [2]
Ependymoma 2A00.0Y Investigative [1]
Neoplastic meningitis N.A. Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EB02: Erlotinib
L01EB: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 393.4
Logarithm of the Partition Coefficient (xlogp) 3.3
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
59% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.69 mL/min/kg [5]
Elimination
0.3% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 36.2 hours [5]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.446 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.07% [5]
Vd
The volume of distribution (Vd) of drug is 232 L []
Water Solubility
The ability of drug to dissolve in water is measured as 0.4 mg/mL [3]
Chemical Identifiers
Formula
C22H23N3O4
IUPAC Name
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
Canonical SMILES
COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC
InChI
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
InChIKey
AAKJLRGGTJKAMG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
176870
ChEBI ID
CHEBI:114785
CAS Number
183321-74-6
UNII
J4T82NDH7E
DrugBank ID
DB00530
TTD ID
D07POC
VARIDT ID
DR00558
INTEDE ID
DR0603
ACDINA ID
D00239
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Drug Response [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Adrenal gland neoplasm
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 2.09E-05 0.4 190.08
Epidermal growth factor receptor (EGFR) DTT EGFR 6.32E-04 0.39 1.69
P-glycoprotein 1 (ABCB1) DTP P-GP 3.21E-01 -1.31E-01 -9.67E-02
Breast cancer resistance protein (ABCG2) DTP BCRP 9.24E-02 -8.49E-01 -5.22E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.80E-01 -3.78E-02 -2.75E+00
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.78E-06 -1.01E+00 -3.20E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 7.76E-01 -2.05E-01 -5.72E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.78E-01 -1.22E-03 -4.10E-03
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.73E-01 -1.42E-01 -5.35E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 2.09E-09 -9.49E-01 -8.32E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.50E-01 -9.32E-02 -1.01E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.15E-08 -6.60E-01 -3.96E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 3.1979 5.5801 0.1794 1.3459
EW-24 GDSC1; GDSC2 -0.1789 5.1739 -2.1356 22.9141
CADO-ES1 GDSC2 1.2533 7.837 -2.2098 18.6207
CHSA8926 GDSC2 1.6559 4.309 -0.1448 5.5476
EW-7 GDSC2 1.7294 5.5604 -0.7045 8.8101
ES6 GDSC1; GDSC2 1.9078 11.4855 -3.5068 22.5326
NOS-1 [Human HNSCC] GDSC1; GDSC2 1.9516 11.8974 -3.6774 23.0608
EW-1 GDSC1; GDSC2 2.2664 4.8264 0.0109 3.397
ES8 GDSC1; GDSC2 2.3176 5.203 -0.1313 4.1138
EW-22 GDSC2 2.3287 5.0694 -0.0629 3.7051
SK-PN-DW GDSC1; GDSC2 2.4436 5.3411 -0.1181 3.8175
NY GDSC2 2.6359 5.3407 -0.0063 2.9007
EW-13 GDSC1; GDSC2 2.8895 4.8297 0.3374 0.9859
EW-11 GDSC1; GDSC2 3.0268 8.2381 -1.1015 8.2865
EW-16 GDSC1; GDSC2 3.086 10.9442 -2.3592 14.7013
EW-18 GDSC1; GDSC2 3.0968 5.6118 0.1184 1.7058
CAL-72 GDSC2 3.1838 5.0655 0.3736 0.6462
ES1 GDSC1; GDSC2 3.1927 11.6449 -2.6243 15.6995
Hs 888.T CTRP2 3.2172 9.2347 1.7441 24.1821
ES7 GDSC1; GDSC2 3.2958 5.8248 0.1264 1.4733
HuO9 GDSC2 3.4561 6.1408 0.0739 1.541
EW-12 GDSC1; GDSC2 3.4834 5.974 2.1279 6.8565
SK-ES-1 GDSC1; GDSC2; CTRP2; CCLE 3.5515 7.1411 2.9617 18.7441
HuO-3N1 GDSC2 3.6293 5.9187 0.2368 0.8064
ES5 GDSC1; GDSC2 3.8108 6.055 2.3383 4.7708
H-EMC-SS GDSC1; GDSC2 4.2529 6.3878 0.3096 0.337
CHSA0108 GDSC2 4.5303 13.162 -0.6309 19.4974
U-CH2 GDSC2 4.6675 9.3728 1.3312 9.0788
EW-3 GDSC1; GDSC2 4.7824 6.6923 0.3919 0.1117
CHSA0011 GDSC2 5.0827 8.113 2.1859 3.4022
TC-71 GDSC1; GDSC2; CCLE 5.1421 6.9599 2.396 0.5007
MHH-ES-1 GDSC2; CTRP2; CCLE 5.1638 8.8248 3.866 11.0086
ES4 GDSC1; GDSC2 5.1796 14.8526 -2.8302 12.7091
SaOS-2 GDSC2; CTRP2; CCLE 5.2976 8.0198 4.3816 8.578
SK-N-MC CTRP2 5.6815 8.9861 4.2611 8.2264
U2OS GDSC2; CTRP2; CCLE 5.6856 9.6338 3.9426 9.549
CAL-78 GDSC2; CTRP2; CCLE 5.8226 10.1858 3.7861 9.9218
A-673 GDSC2; CTRP2; CCLE 6.3869 10.2192 4.2351 6.9677
TC71 CTRP2 6.4608 9.9403 4.4317 6.0159
Hs 822.T CTRP2 6.6526 10.4563 4.3225 6.1439
SJSA-1 GDSC1; GDSC2; CTRP2; CCLE 6.7897 10.4731 4.4163 5.5312
MG-63 GDSC2; CTRP2; CCLE 7.395 11.5201 4.3339 4.9606
SW1353 CTRP2; CCLE 7.4651 11.1002 4.5797 3.8931
G-292 clone A141B1 GDSC2; CTRP2 7.7103 13.4191 3.6361 7.2953
HOS GDSC2; CTRP2; CCLE 7.8626 13.5308 3.6866 6.8769
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 223 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 1.1957 4.6389 1.0598 32.7494
MEC1 CTRP2 4.5295 7.3767 3.9034 12.4274
JM1 GDSC1; GDSC2; CTRP2 5.9077 9.0401 4.4311 7.0493
GA-10 GDSC1; GDSC2 0.1783 4.1246 -1.2907 16.9728
MOLM-16 GDSC2; CTRP2 1.004 4.0045 0.9376 33.7976
P30/OHK GDSC1; GDSC2 1.3964 3.5666 0.0302 5.0795
Sc-1 GDSC1 1.4338 3.4931 0.0939 5.7191
Karpas-231 GDSC1; GDSC2 1.4753 3.535 0.1035 4.4348
SUP-B8 GDSC2 1.4758 4.6506 0.8357 22.0384
Jiyoye GDSC1; GDSC2 1.5116 4.0159 -0.1057 5.6451
MHH-CALL-2 GDSC2 1.5615 4.3504 -0.2334 6.3172
EoL-1 GDSC1; GDSC2; CTRP2 1.6361 2.5282 1.6361 29.3689
Hs 445 GDSC1; GDSC2 1.6727 4.7007 -0.324 6.6119
SCC-3 GDSC1; GDSC2 1.6751 3.1969 0.4002 2.2248
MV4-11 GDSC1; GDSC2; CTRP2 1.6901 4.1697 1.6434 29.1653
JVM-2 GDSC1; GDSC2 1.7267 3.4788 0.3012 2.7039
JSC-1 GDSC1; GDSC2 1.8176 4.1061 0.064 3.9276
H9 GDSC1; GDSC2 1.8259 4.1484 0.0495 3.9977
BE-13 GDSC1; GDSC2 1.8345 3.9158 0.1651 3.2955
CTB-1 GDSC1; GDSC2 1.8461 5.693 0.7587 20.2622
KMS-26 CTRP2; CCLE 1.8543 2.959 1.854 27.916
KOPN-8 GDSC1; GDSC2 1.8552 4.5644 -0.1297 5.0133
SU-DHL-5 GDSC2 1.864 7.3517 -1.4877 13.0843
TK [Human B-cell lymphoma] GDSC1; GDSC2 1.9087 3.6896 0.3159 2.2943
697 GDSC1; GDSC2; CTRP2; CCLE 1.9543 3.62 1.9474 27.2719
Karpas-1106P GDSC2 1.9685 3.7032 0.3447 2.0375
P32/ISH GDSC1; GDSC2 2.0396 4.4003 0.0683 3.4725
MOLM-13 GDSC1; GDSC2; CTRP2 2.0693 4.5551 2.0038 26.7037
Pfeiffer CTRP2; CCLE 2.1084 3.5643 2.1049 26.2336
ME1 GDSC1; GDSC2 2.1691 3.6162 0.4899 1.0345
MOLT-4 GDSC1; GDSC2 2.183 4.4503 0.1326 2.8574
NOMO-1 GDSC1; GDSC2 2.2004 3.7023 0.4696 1.0927
CCRF-CEM GDSC1; GDSC2 2.244 4.2733 0.2469 2.1424
VAL GDSC1; GDSC2 2.2755 4.3372 0.2362 2.1527
CESS GDSC1; GDSC2 2.2972 4.0202 0.3848 1.377
JURL-MK1 GDSC1; CTRP2 2.3194 4.2704 2.293 24.9049
HC-1 GDSC1; GDSC2 2.3485 7.1753 -1.0489 9.4094
SEM CTRP2 2.3919 4.4281 2.3566 24.4523
HAL-01 GDSC1; GDSC2 2.4358 4.302 0.3364 1.4426
ALL-PO GDSC1; GDSC2 2.4506 7.1524 -0.9673 8.7133
BALL-1 GDSC1; GDSC2 2.4944 4.3398 0.3498 1.3145
NCO2 CTRP2; CCLE 2.5051 4.2612 2.4862 23.6425
CTV-1 GDSC1; GDSC2 2.5669 4.3343 0.3871 1.0759
IM-9 GDSC1; GDSC2 2.5799 3.9537 0.5421 0.4823
BV-173 GDSC1; GDSC2; CTRP2 2.5841 4.6702 2.5357 23.2162
Karpas-45 GDSC1; GDSC2 2.5938 5.394 -0.0539 3.2189
Ku812 GDSC1; GDSC2; CTRP2; CCLE 2.5972 4.0195 2.5909 22.9869
Mono-Mac-1 CTRP2; CCLE 2.6074 5.665 2.3899 23.6482
Ramos.2G6.4C10 GDSC1; GDSC2 2.6499 4.2925 0.4418 0.7831
KYO-1 CTRP2 2.6816 4.704 2.6351 22.56
Peer CTRP2 2.7186 3.756 2.7178 22.1597
MLMA GDSC1; GDSC2 2.7387 4.6999 0.3199 1.1936
NU-DUL-1 GDSC1; GDSC2; CTRP2 2.7404 4.1449 2.7332 22.0359
KMOE-2 GDSC1; GDSC2 2.7522 5.2476 0.0975 2.2076
JVM-3 GDSC1; GDSC2; CTRP2; CCLE 2.8007 5.4168 2.6539 22.1138
LAMA-84 GDSC1; GDSC2; CTRP2 2.8113 4.4903 2.7894 21.6129
Loucy GDSC1; GDSC2 2.861 9.0579 -1.6033 11.3689
ATN-1 GDSC1; GDSC2 2.8698 5.2684 0.1491 1.8162
L-1236 GDSC1; GDSC2 2.87 4.909 0.2969 1.1654
CMK-86 CCLE 2.875 5.583 1.6029 7.8862
MOLT-16 GDSC1; GDSC2; CTRP2; CCLE 2.9221 4.9909 2.8561 21.0248
YT GDSC1; GDSC2 2.9492 4.422 0.5173 0.3575
MOLT-13 GDSC2; CTRP2 2.9705 4.6964 2.9397 20.5821
KE-37 GDSC1; GDSC2; CTRP2 3.0009 5.387 2.8766 20.7019
KG-1 GDSC1; GDSC2; CCLE 3.0074 4.937 2.0377 5.0563
SU-DHL-16 GDSC1; GDSC2 3.008 4.2671 2.5676 5.5746
RC-K8 GDSC1; GDSC2 3.0153 4.31 0.582 0.1903
KY821 GDSC1; GDSC2 3.039 4.3375 0.5811 0.1852
MHH-PREB-1 GDSC1; GDSC2 3.0622 4.5471 0.5158 0.3134
TUR GDSC1; GDSC2 3.0638 4.6347 0.4848 0.3893
L-540 GDSC1; GDSC2; CTRP2 3.0995 4.2572 3.0956 19.6323
Farage GDSC1; GDSC2 3.121 5.2892 2.1662 7.649
ALL-SIL GDSC1; GDSC2; CTRP2; CCLE 3.1389 5.3016 3.041 19.691
WSU-NHL GDSC1; GDSC2 3.1452 5.2113 0.3014 0.9177
BC-3 GDSC1; GDSC2 3.1475 4.3621 2.6502 4.6235
BONNA-12 GDSC2 3.1504 6.1619 1.7566 10.4103
MN-60 GDSC1; GDSC2 3.1604 5.085 0.3564 0.7162
DG-75 GDSC1; GDSC2 3.176 4.99 0.3987 0.5734
VL51 GDSC1; GDSC2 3.2037 5.0926 0.3716 0.6402
ARH-77 GDSC1; GDSC2 3.2594 5.0138 0.4233 0.4596
ML-2 GDSC1; GDSC2 3.2849 4.7766 0.5178 0.2313
EM-2 GDSC1; GDSC2; CTRP2; CCLE 3.3127 5.4292 3.2059 18.5645
MOLM-6 CTRP2 3.3253 5.4189 3.2214 18.4706
Jurkat GDSC2; CTRP2; CCLE 3.3267 6.0947 3.0646 19.0238
OCI-Ly7 GDSC2 3.33 5.3837 2.2978 6.4606
SET-2 CTRP2 3.3711 5.6762 3.2186 18.336
LC4-1 GDSC1; GDSC2 3.3756 5.315 0.3588 0.581
Mino CTRP2; CCLE 3.4138 6.717 2.9653 19.1278
RPMI-8866 GDSC1 3.4373 5.1705 0.4355 0.4388
DoHH2 GDSC1; GDSC2; CCLE 3.5145 5.0164 2.6294 3.2111
SKM-1 GDSC1; GDSC2; CTRP2 3.5284 5.1354 3.483 16.9155
KE-97 CTRP2; CCLE 3.5462 6.9924 3.011 18.5737
DB GDSC1; GDSC2; CTRP2 3.5577 6.7482 3.1103 18.1695
WSU-DLCL2 GDSC1; GDSC2; CTRP2 3.558 6.1092 3.313 17.4236
Ki-JK CTRP2 3.5936 5.5998 3.4767 16.7293
NU-DHL-1 CTRP2 3.598 6.8567 3.1157 18.0328
Kasumi-2 CTRP2; CCLE 3.6144 6.5068 3.2532 17.4739
Karpas-299 GDSC1; GDSC2; CTRP2; CCLE 3.688 4.991 3.6661 15.7725
MEG-01 GDSC1; GDSC2; CCLE 3.6882 6.5883 1.742 5.1404
GR-ST GDSC1; GDSC2 3.7394 5.8163 0.3191 0.509
DEL GDSC1; GDSC2; CTRP2; CCLE 3.773 5.6598 3.659 15.5246
P31/FUJ GDSC1; GDSC2; CTRP2; CCLE 3.7786 6.616 3.3949 16.4673
SU-DHL-10 GDSC2; CTRP2; CCLE 3.7922 5.7678 3.6562 15.4745
NKM-1 GDSC1; GDSC2 3.7988 5.7704 0.3584 0.3895
Daudi GDSC1; GDSC2; CTRP2 3.8106 6.5169 3.4629 16.1212
RPMI-8402 GDSC1; GDSC2; CTRP2; CCLE 3.8351 6.0682 3.6268 15.448
MEC-1 CCLE 3.8715 6.3794 1.9698 3.7496
CML-T1 GDSC2; CTRP2 3.9431 5.8097 3.8108 14.4569
A4/Fukuda GDSC1; GDSC2; CTRP2 3.9493 6.4928 3.6215 15.1266
SU-DHL-6 GDSC1; GDSC2; CTRP2; CCLE 3.9546 6.2438 3.7063 14.799
MY-M12 GDSC1; GDSC2 3.9854 7.2565 1.8765 7.1295
ROS-50 GDSC1; GDSC2 4.0162 6.3874 2.3222 4.415
WIL2 NS GDSC1; GDSC2 4.0383 11.8195 -2.1357 11.6701
BC-1 GDSC1; GDSC2 4.0842 5.7108 0.4812 0.1143
HEL GDSC1; GDSC2; CTRP2 4.0896 7.392 3.4361 15.4331
KMS-20 CTRP2 4.0905 8.3188 3.0418 16.9659
CRO-AP2 GDSC2 4.0949 6.8403 2.1579 5.4007
EB1 CTRP2; CCLE 4.1277 6.8688 3.6813 14.3885
RS4;11 GDSC1; GDSC2; CTRP2 4.1341 7.5915 3.4004 15.4505
L-428 GDSC1; GDSC2; CTRP2; CCLE 4.1362 7.4667 3.4545 15.2349
RPMI-8226 GDSC1; GDSC2; CTRP2 4.1394 6.7627 3.7329 14.1601
HDLM-2 GDSC1; GDSC2; CTRP2 4.1485 8.4286 3.0521 16.7748
Ci-1 CCLE 4.2402 5.2178 2.6781 0.2283
PL-21 GDSC1; GDSC2 4.2882 6.5426 2.428 3.2729
BL-41 GDSC1; GDSC2; CCLE 4.2971 7.4135 1.7578 3.9937
NALM-6 GDSC1; GDSC2; CTRP2 4.3026 6.7407 3.9164 13.0019
M-07e CTRP2 4.3202 11.1178 1.9585 20.5407
KMS-12-BM GDSC2; CTRP2; CCLE 4.4103 7.2166 3.8453 12.9747
RCH-ACV GDSC2; CTRP2 4.4309 7.7147 3.656 13.6599
GDM-1 GDSC1; GDSC2; CTRP2 4.4396 6.8284 4.0304 12.1818
PF-382 GDSC1; GDSC2; CTRP2 4.4623 7.2648 3.8801 12.6987
F-36P CTRP2; CCLE 4.4842 9.8418 2.7282 17.2094
NK-92MI GDSC1; GDSC2 4.5175 10.0547 0.8925 11.5609
KCL-22 GDSC1; GDSC2; CTRP2; CCLE 4.5216 7.1123 4.0051 12.0526
KMS-34 CTRP2; CCLE 4.53 6.7795 4.1456 11.4891
U-698-M GDSC1; GDSC2 4.5492 12.8482 -2.2921 11.458
SUP-B15 GDSC1; GDSC2; CTRP2 4.5749 6.8848 4.1526 11.337
RPMI-6666 GDSC1; GDSC2; CTRP2 4.5821 7.6648 3.8333 12.5648
BDCM CCLE 4.6384 6.9801 2.1525 1.782
OCI-Ly19 GDSC1; GDSC2; CTRP2 4.7096 8.3501 3.6517 12.9669
OCI-Ly3 CTRP2 4.7437 7.3771 4.125 10.9893
CMK CTRP2 4.7491 7.3323 4.15 10.8763
SU-DHL-1 GDSC1; GDSC2; CTRP2 4.7537 6.5299 4.4787 9.5924
MHH-CALL-3 CTRP2 4.7916 10.772 2.5697 17.1025
Ri-1 CTRP2 4.7999 8.3795 3.7273 12.4393
QIMR-WIL GDSC1; GDSC2 4.8048 9.302 1.4592 7.7729
Reh GDSC1; GDSC2; CTRP2; CCLE 4.8136 7.3534 4.2074 10.4807
SIG-M5 GDSC1; GDSC2; CTRP2; CCLE 4.8284 8.2843 3.7998 12.0763
MHH-CALL-4 GDSC2; CTRP2 4.8504 7.9466 3.978 11.3027
Toledo CCLE 4.9249 6.88 2.3335 0.8316
Hs 611.T CTRP2 4.9593 8.5567 3.7993 11.7613
JM-1 CCLE 4.9651 6.5025 2.4942 0.3519
A3/Kawakami GDSC1; GDSC2; CTRP2 4.9654 9.1413 3.5252 12.8655
HuT 78 CTRP2; CCLE 4.9976 10.8683 2.7128 16.0688
SUP-M2 GDSC1; GDSC2; CTRP2; CCLE 5.0129 6.0903 4.9058 7.2483
SUP-T1 GDSC1; GDSC2; CTRP2; CCLE 5.044 7.7724 4.2511 9.7205
P12-Ichikawa GDSC2; CTRP2; CCLE 5.0482 8.4119 3.9542 10.9175
OCI-AML-2 GDSC1; GDSC2; CTRP2; CCLE 5.055 7.4678 4.402 9.0853
MOTN-1 CTRP2 5.0921 8.3119 4.0443 10.4452
HPB-ALL CTRP2 5.098 7.4838 4.4379 8.8332
Kasumi-1 GDSC1; GDSC2; CTRP2 5.1016 7.1698 4.5831 8.2431
KM-H2 GDSC1; GDSC2; CTRP2 5.1114 8.7184 3.8679 11.1222
EHEB GDSC1; CTRP2 5.1157 9.0074 3.7323 11.6691
EB2 GDSC1; GDSC2; CCLE 5.1164 7.5748 2.1431 1.3137
KMS-11 GDSC2; CTRP2; CCLE 5.2371 7.9139 4.3739 8.7524
SU-DHL-8 GDSC1; GDSC2; CTRP2; CCLE 5.2621 8.0964 4.3109 8.9516
HH [Human lymphoma] GDSC1; GDSC2; CTRP2; CCLE 5.3436 8.7195 4.0857 9.6927
SU-DHL-4 GDSC1; GDSC2; CTRP2; CCLE 5.3474 8.8722 4.0146 9.9783
K-562 GDSC1; GDSC2; CTRP2 5.3549 8.2885 4.3063 8.7551
Namalwa GDSC1; GDSC2; CTRP2 5.3796 8.7596 4.0995 9.5549
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 5.4558 9.3417 3.8828 10.2863
U-937 CTRP2; CCLE 5.467 8.6273 4.245 8.7569
KHM-1B CTRP2; CCLE 5.4782 8.9053 4.1184 9.2582
MC116 GDSC1; GDSC2; CTRP2; CCLE 5.4873 9.9294 3.6201 11.3083
OPM-2 GDSC1; GDSC2; CTRP2; CCLE 5.537 8.1644 4.5366 7.3902
NB4 GDSC1; GDSC2; CTRP2 5.5696 8.8173 4.2448 8.5332
U266B1 GDSC1; GDSC2; CTRP2 5.6071 10.5989 3.3932 11.9927
MJ CCLE 5.631 7.8646 2.2579 0.6327
PL21 CTRP2 5.7969 9.3635 4.1743 8.3505
SUP-HD1 GDSC1; GDSC2; CTRP2 5.8149 7.8936 4.9222 5.1796
CA46 GDSC1; GDSC2; CTRP2 5.892 9.1822 4.3468 7.4349
JeKo-1 GDSC2; CTRP2 6.0371 10.0761 4.0225 8.5095
L-363 GDSC1; GDSC2; CTRP2; CCLE 6.0689 9.9436 4.1152 8.0598
KO52 CTRP2; CCLE 6.1637 10.2341 4.0481 8.1601
HEL 92.1.7 CTRP2; CCLE 6.1822 9.9616 4.1994 7.4913
MOLP-8 GDSC1; GDSC2; CTRP2; CCLE 6.2007 7.8551 5.2658 2.9834
LP-1 GDSC1; GDSC2; CTRP2; CCLE 6.2105 8.7083 4.8482 4.7167
KMS-21-BM CTRP2 6.2178 8.4562 4.9798 4.1514
Karpas-422 GDSC1; GDSC2; CTRP2; CCLE 6.2262 8.949 4.7407 5.1389
HL-60 GDSC1; GDSC2; CTRP2 6.3247 9.0621 4.7623 4.8718
HuNS1 CTRP2 6.3345 10.008 4.2989 6.7948
AML-193 CTRP2 6.4178 13.4536 2.6462 13.4053
OCI-M1 GDSC1; GDSC2; CTRP2 6.4879 8.1211 5.3484 2.1723
ST486 GDSC1; GDSC2; CTRP2 6.5496 9.5417 4.6968 4.7607
HD-MY-Z CTRP2; CCLE 6.5631 11.1549 3.9075 8.0211
KMS-18 CTRP2 6.5766 8.9565 5.0045 3.4446
TF-1 CTRP2 6.6224 10.4734 4.2912 6.3247
OCI-AML-3 GDSC1; GDSC2; CTRP2 6.6449 9.2233 4.9233 3.6719
KMS-28BM CTRP2 6.6626 9.9157 4.5967 4.9906
AMO1 GDSC1; GDSC2; CTRP2; CCLE 6.6944 9.2332 4.9539 3.4711
OCI-Ly10 CTRP2; CCLE 6.8401 10.1087 4.6312 4.5688
SUP-T11 CTRP2 6.9082 9.8572 4.8011 3.7754
MM1.S GDSC2; CTRP2 6.9425 9.4587 5.0152 2.8685
KMS-27 CTRP2 6.9615 8.9795 5.2525 1.9193
DND-41 GDSC1; GDSC2; CTRP2 7.005 12.1191 3.7657 7.8599
SR GDSC1; GDSC2; CTRP2 7.1295 9.9891 4.8865 3.128
HT GDSC1; GDSC2; CTRP2; CCLE 7.1452 9.1928 5.2654 1.6617
THP-1 GDSC1; GDSC2; CTRP2 7.186 9.8289 4.9978 2.622
RL GDSC1; GDSC2; CTRP2 7.2925 8.7597 5.5319 0.6382
Mono-Mac-6 GDSC1; GDSC2; CTRP2 7.2979 12.9674 3.5638 8.2107
BL-70 CTRP2; CCLE 7.3383 8.4965 5.6569 0.2894
EJM GDSC1; GDSC2; CTRP2 7.3609 9.9153 5.0649 2.1634
MOLP-2 CTRP2 7.4024 11.8163 4.1968 5.4995
Granta-519 GDSC1; GDSC2; CTRP2; CCLE 7.4035 9.4252 5.3071 1.2605
P3HR-1 CTRP2; CCLE 7.5477 9.2498 5.4537 0.6925
OCI-AML-5 GDSC1; CTRP2; CCLE 7.7602 14.7587 3.0212 9.6429
Karpas-620 GDSC2; CTRP2; CCLE 7.9097 9.4207 5.5453 0.2945
SK-MM-2 GDSC1; GDSC2; CTRP2; CCLE 7.9404 9.5445 5.5117 0.3494
Raji GDSC1; GDSC2; CTRP2; CCLE 7.9938 9.498 5.5503 0.2571
ME1 CTRP2 8.2053 11.3786 4.89 1.9445
NCI-H929 GDSC2; CTRP2 8.2822 9.7277 5.5775 0.1437
KMM-1 CTRP2; CCLE 8.4599 10.7006 5.2909 0.6079
JJN-3 GDSC1; GDSC2; CTRP2 9.4554 18.9609 2.1597 10.3944
⏷ Show the Full List of 223 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 2.087 8.9767 0.6803 30.9654
TE8 CTRP2 5.2933 10.7358 3.0467 14.0772
OE21 GDSC2; CTRP2; CCLE -0.598 5.0837 -0.9667 44.8601
T.T GDSC2 0.4937 6.7511 -2.3076 21.4485
TE-15 GDSC1; CCLE 0.5656 3.9778 0.0242 23.398
KYSE-140 GDSC2; CTRP2; CCLE 0.6941 5.1034 0.4329 36.4346
KYSE-270 GDSC2 1.4844 8.7331 -2.4706 19.2402
TE-11 GDSC2; CTRP2; CCLE 1.5061 6.214 1.0443 31.7488
TE-14 CTRP2 2.4301 9.7629 0.7043 29.8433
TE-6 GDSC1; GDSC2; CTRP2 2.7902 10.6198 0.6908 28.8282
TE-4 GDSC2; CTRP2 2.9964 7.3682 2.2816 22.8676
KYSE-410 GDSC2; CTRP2; CCLE 3.0274 7.9275 2.098 23.4474
TE-9 GDSC1; GDSC2; CTRP2; CCLE 4.4872 9.6997 2.7988 16.9244
COLO 680N GDSC2; CTRP2 4.7312 12.7927 1.5218 21.1286
TE-10 GDSC1; GDSC2; CTRP2 4.8474 10.7646 2.6252 16.7567
KYSE-70 GDSC2; CTRP2; CCLE 5.0182 9.3179 3.4898 12.8876
TE-5 GDSC1; GDSC2; CTRP2; CCLE 5.056 9.1168 3.6228 12.256
TE-8 GDSC1; GDSC2 5.2452 14.8495 -2.7876 12.4172
KYSE-180 GDSC2; CTRP2; CCLE 5.2504 13.2751 1.7478 19.1623
KYSE-150 GDSC2; CTRP2; CCLE 5.5857 9.8272 3.7583 10.526
KYSE-520 GDSC2; CTRP2; CCLE 5.7343 13.3698 2.1202 16.7686
OE33 GDSC2; CTRP2; CCLE 5.9829 10.7746 3.6279 10.2615
EC-GI-10 GDSC1; GDSC2; CTRP2 6.0617 13.526 2.318 15.36
OE19 GDSC2; CTRP2 6.3668 11.8029 3.4292 10.3523
TE-1 GDSC1; GDSC2; CTRP2; CCLE 7.0033 16.1174 1.783 15.5627
KYSE-510 GDSC2; CTRP2; CCLE 7.7245 15.3583 2.7026 10.9284
KYSE-30 CTRP2; CCLE 9.1539 22.7661 0.1121 17.3787
KYSE-450 GDSC2; CTRP2; CCLE 10.3642 27.8757 -1.5141 19.8404
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 7.673 16.3204 2.1924 12.9268
KCI-MOH1 CCLE 1.2737 4.2224 0.6833 17.6304
HuP-T4 GDSC2; CTRP2; CCLE 1.7282 6.7363 1.1284 30.7457
PK-1 CCLE 3.2129 7.0418 1.1537 9.4708
L3.3 CTRP2; CCLE 3.6123 9.8968 1.8457 22.7489
PL45 CCLE 3.9004 7.2217 1.5843 5.6962
BxPC-3 GDSC2; CTRP2; CCLE 4.1981 9.5899 2.5688 18.5361
SUIT-2 GDSC2; CTRP2; CCLE 4.3374 7.8207 3.5136 14.4665
SNU-213 CTRP2 4.3813 10.9111 2.1163 19.808
KP-1NL CCLE 4.7479 7.5765 1.9519 2.5304
KP-3 GDSC2; CTRP2; CCLE 4.759 8.5192 3.6217 12.9665
PaTu 8988s CTRP2 4.9067 16.0199 0.0795 25.256
Hs 766T GDSC2; CTRP2; CCLE 4.9162 11.8578 2.1512 18.4225
KP-1N GDSC2; CCLE 5.1291 8.468 2.0533 3.2857
SW1990 GDSC2; CTRP2; CCLE 5.2716 9.6373 3.5693 11.9877
PL4 GDSC2 5.3543 7.8498 2.4436 1.4279
Panc 05.04 CTRP2 5.4274 13.8464 1.618 19.2422
HPAF-II GDSC2; CTRP2; CCLE 5.5779 12.706 2.3173 16.3477
MZ-PC-1 GDSC1; GDSC2 5.7198 12.9125 0.3478 11.8036
KP-2 GDSC2; CCLE 5.7823 10.596 1.4732 5.0005
Panc 08.13 GDSC2; CTRP2 6.0704 12.9555 2.6105 14.2125
MIA PaCa-2 GDSC2; CTRP2; CCLE 6.336 9.4759 4.5652 5.677
Panc 03.27 GDSC2; CTRP2; CCLE 6.435 16.5111 1.1328 18.8586
QGP-1 GDSC2; CTRP2; CCLE 6.4352 11.7471 3.5118 9.887
Panc 02.03 GDSC2; CTRP2; CCLE 6.5035 12.0863 3.3971 10.2342
Capan-1 GDSC2; CTRP2 6.5942 12.6273 3.1992 10.8765
PK-59 CTRP2; CCLE 6.6728 11.4757 3.833 8.1393
KP-4 GDSC2; CTRP2; CCLE 6.6936 10.3963 4.383 5.8251
HPAC GDSC2; CTRP2; CCLE 6.9482 19.3404 0.1338 20.9821
TCC-Pan2 CTRP2 7.0294 10.4091 4.6184 4.3383
SU.86.86 GDSC2; CTRP2; CCLE 7.1215 14.2336 2.8092 11.5072
Capan-2 GDSC2; CTRP2; CCLE 7.1317 14.872 2.5008 12.6821
AsPC-1 GDSC2; CTRP2; CCLE 7.2626 13.2779 3.3858 8.9834
PK-45H CTRP2; CCLE 7.3788 9.9392 5.0647 2.1445
YAPC GDSC2; CTRP2 7.495 14.6096 2.9023 10.524
DAN-G GDSC2; CTRP2 7.5183 21.9642 -0.723 22.294
CFPAC-1 GDSC2; CTRP2 7.6833 20.9195 -0.0753 20.2749
PSN1 GDSC1; GDSC2; CTRP2; CCLE 7.9916 11.7538 4.6029 3.1725
Panc 10.05 GDSC2; CTRP2; CCLE 8.0582 16.3182 2.4737 11.2706
PaTu 8902 GDSC2; CTRP2; CCLE 8.0775 13.2317 3.9709 5.4729
SNU-410 CTRP2 8.1029 17.4829 1.9368 13.1583
HuP-T3 GDSC2; CTRP2; CCLE 8.5349 15.887 3.0119 8.5461
Panc 04.03 GDSC2; CTRP2; CCLE 10.1311 23.7504 0.3224 15.3605
PaTu 8988t GDSC2; CTRP2 12.8278 29.0485 -0.4155 14.0085
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 79 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 4.651 13.1306 1.2822 22.1359
A-388 GDSC1; GDSC2 0.6981 6.9316 -0.9586 32.8362
A-431 GDSC2 0.8291 5.6485 -0.2585 30.4248
CHL-1 GDSC2; CCLE 1.8511 4.4148 1.2 12.6968
M14 GDSC2 1.8525 7.6638 -1.6508 14.0221
WM278 GDSC2 2.1816 11.727 -3.4134 21.463
HMV-II GDSC2 2.194 5.8753 -0.5287 6.6872
GAK GDSC2 2.5275 4.0673 0.4757 0.7533
WM35 GDSC2 2.5519 6.9958 -0.8241 7.6717
COLO 741 CCLE 2.6545 6.4276 0.9904 11.7602
IST-MEL1 GDSC1; GDSC2 2.7312 4.7038 0.3147 1.223
SH-4 GDSC1; GDSC2 2.8891 4.9128 0.3042 1.1181
COLO 679 GDSC2; CCLE 3.1163 4.5456 2.3218 3.3044
G-361 GDSC2; CTRP2; CCLE 3.136 6.0944 2.8566 20.354
MZ-MEL-2 GDSC1; GDSC2 3.364 5.4821 2.2767 6.2716
WM1552C GDSC2 3.3932 5.2517 0.3891 0.4869
G-mel GDSC2 3.6297 6.2709 2.0955 6.9131
MZ-MEL-7 GDSC1; GDSC2 3.7861 8.134 1.2909 11.0896
DJM-1 GDSC1; GDSC2 3.8318 11.1945 -0.1979 18.8699
451Lu GDSC2 4.0329 5.95 2.5427 3.2089
WM1799 CTRP2; CCLE 4.4618 8.6394 3.2717 15.1075
COLO 783 GDSC2 4.5738 6.4811 2.6232 1.8487
VMRC-MELG GDSC2 4.8294 12.2323 0.0521 15.6063
MMAc-SF GDSC1; GDSC2 4.8317 7.4204 2.3521 2.796
CP66-MEL GDSC1; GDSC2 4.9259 11.6153 0.424 13.1057
WM88 CTRP2; CCLE 4.9716 7.6962 4.2141 10.0497
Hs 938.T GDSC2; CCLE 4.9828 6.9739 2.6241 1.1239
WT2-iPS GDSC2; CCLE 5.1647 7.2734 2.5888 1.0685
CP50-MEL-B GDSC2 5.349 14.1823 -0.5256 17.0685
IPC-298 GDSC2; CTRP2; CCLE 5.4092 10.4483 3.293 12.8235
Mel Ho GDSC2; CTRP2; CCLE 5.4296 8.0927 4.4716 7.9016
SF8657 CCLE 5.4647 7.5275 2.3159 0.5637
COLO 792 GDSC2; CTRP2 5.492 9.0338 4.0676 9.4393
WM793 GDSC2; CTRP2; CCLE 5.5629 9.3903 3.955 9.7557
Hs 934.T CTRP2 5.6801 11.3596 3.0774 13.1332
LOX-IMVI GDSC1; GDSC2; CTRP2; CCLE 5.7033 9.395 4.077 8.9505
LB2518-MEL GDSC1; GDSC2 5.7631 15.0109 -0.6343 16.2104
Hs 695T CCLE 5.917 9.0395 1.9265 1.474
RPMI-7951 GDSC2; CTRP2; CCLE 5.9604 9.7386 4.1268 8.2218
MeWo GDSC2; CTRP2; CCLE 5.9834 11.1974 3.4169 11.1338
WM115 GDSC2; CTRP2; CCLE 5.9907 9.6731 4.1851 7.9179
Hs 944.T CTRP2; CCLE 6.2976 10.0768 4.2352 7.1284
A2058 GDSC2; CTRP2; CCLE 6.3257 7.5294 5.5212 1.7119
COLO 800 GDSC1; GDSC2; CTRP2 6.3624 12.2857 3.1847 11.3597
Hs 940.T GDSC2; CTRP2 6.3974 11.9635 3.3736 10.5239
HMCB CTRP2; CCLE 6.4247 10.2417 4.2537 6.8227
Hs 294T CTRP2; CCLE 6.4249 10.3188 4.2154 6.9822
IGR-39 CTRP2; CCLE 6.4971 10.0954 4.3827 6.1574
IGR-1 GDSC2; CTRP2 6.5487 12.1556 3.3983 10.1478
Hs 839.T CTRP2 6.5729 10.3213 4.3288 6.2523
RVH-421 GDSC2; CTRP2; CCLE 6.6049 13.2169 2.9138 12.003
Hs 852.T CTRP2; CCLE 6.6635 11.2227 3.9513 7.6656
K029AX CTRP2; CCLE 6.6945 10.1831 4.4887 5.3859
SK-MEL-3 GDSC2; CTRP2 6.6958 12.6326 3.2762 10.3832
CJM [Human melanoma] CTRP2 6.8161 9.3324 4.9906 3.1427
SK-MEL-24 GDSC2; CTRP2; CCLE 6.8662 11.2296 4.1007 6.7096
SK-MEL-2 GDSC1; GDSC2; CTRP2; CCLE 6.8756 8.0089 5.6378 0.6254
WM983B CTRP2; CCLE 6.996 10.8001 4.4054 5.254
Hs 688(A).T CTRP2 7.0024 11.1908 4.2193 6.0053
UACC-257 GDSC1; GDSC2; CTRP2; CCLE 7.0207 8.5538 5.4796 1.0253
SK-MEL-30 GDSC2; CTRP2; CCLE 7.0771 10.1828 4.7597 3.7018
HT-144 GDSC1; GDSC2; CTRP2; CCLE 7.1423 12.2281 3.8129 7.4467
MDA-MB-435S CTRP2; CCLE 7.173 10.444 4.6992 3.8108
SK-MEL-1 GDSC1; GDSC2; CTRP2 7.1879 10.9966 4.4444 4.8114
Hs 895.T CTRP2; CCLE 7.2216 11.3717 4.2866 5.3996
Hs 936.T CTRP2; CCLE 7.418 10.473 4.8432 2.9321
SK-MEL-5 GDSC2; CTRP2; CCLE 7.753 12.5496 4.0818 5.469
WM266-4 CTRP2; CCLE 7.8155 12.5112 4.1411 5.1526
UACC-62 GDSC2; CTRP2; CCLE 8.0755 15.742 2.7663 10.1427
COLO 829 GDSC1; GDSC2; CTRP2 8.1447 16.5264 2.4339 11.2857
SK-MEL-31 GDSC2; CTRP2; CCLE 8.1942 15.1632 3.1284 8.5821
IGR-37 GDSC2; CTRP2; CCLE 8.378 14.3868 3.6208 6.4333
A-375 GDSC2; CTRP2; CCLE 8.4495 14.759 3.4915 6.835
Malme-3M CTRP2; CCLE 8.7146 20.3625 0.9703 15.4581
LB373-MEL-D GDSC1; GDSC2 9.1451 26.0966 -3.6544 20.1074
A101D GDSC1; GDSC2; CTRP2 9.7072 18.4496 2.5639 8.645
Mel JuSo GDSC2; CTRP2 11.443 22.3478 1.8315 9.0651
SK-MEL-28 GDSC2; CTRP2 12.5052 30.5877 -1.3506 16.7076
EquiPSC Line K2 GDSC2 3.3709 8.463 0.7921 15.5691
⏷ Show the Full List of 79 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-12 GDSC1; GDSC2 -2.9348 13.4187 -7.5651 53.5342
KYAE-1 GDSC2 1.2988 5.7915 -1.1516 12.6433
KYSE-50 GDSC2 1.7372 6.9503 -1.3853 12.8301
KYSE-220 GDSC2 1.7729 9.4212 -2.5851 18.9869
ESO-26 GDSC2 2.0844 4.6489 -0.0193 3.8974
OACM5.1 C GDSC2 2.3988 4.7547 0.1204 2.5823
FLO-1 GDSC2 2.5053 7.3667 -1.033 8.9738
OACP4 C GDSC2 2.7317 10.6963 -2.4916 16.1371
ESO-51 GDSC2 3.0566 5.1559 0.2838 1.0538
SK-GT-4 GDSC2 4.0146 14.7544 -3.5557 17.8383
HCE-4 GDSC2 4.9207 7.0917 2.5436 1.7937
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2 2.6713 4.8117 0.2409 1.6167
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-6 GDSC1; GDSC2 1.3824 3.0985 1.2618 19.3969
SJNB-10 GDSC1; GDSC2 2.0402 4.6478 -0.0469 4.1431
NB(TU)1 GDSC1; GDSC2 2.1642 5.0611 -0.1617 4.5762
SJNB-13 GDSC1; GDSC2 2.3025 5.3668 -0.2169 4.6345
IMR-5 GDSC1; GDSC2 2.3849 4.1457 0.3763 1.3148
CHP-134 GDSC2 2.6866 5.1126 0.1209 2.1763
SK-N-BE(2)-M17 GDSC1; GDSC2 2.8165 6.8713 -0.5953 5.8488
TGW GDSC1; GDSC2 3.1255 4.6806 0.4921 0.3441
SJNB-14 GDSC1; GDSC2 3.2629 4.9723 0.4398 0.4147
NB69 GDSC1; GDSC2 3.3087 8.7567 -1.1646 8.0916
SJNB-7 GDSC1; GDSC2 3.5898 5.1872 0.4858 0.2041
GOTO GDSC1; GDSC2 3.6497 6.1297 0.165 1.0339
NH-12 GDSC1; GDSC2 3.7605 5.5478 0.4226 0.2697
SK-N-MC-IXC GDSC2 3.8258 6.2551 2.2511 5.4469
SJNB-12 GDSC1; GDSC2 3.834 5.7936 0.3634 0.3655
LA-N-6 GDSC1; GDSC2 3.9264 5.8948 2.4978 3.5723
KP-N-RT-BM-1 GDSC2 3.9945 7.0547 1.982 6.7103
SJNB-17 GDSC1; GDSC2 4.1847 9.4454 0.9461 12.0572
IMR-32 CCLE 4.2797 5.2961 2.665 0.2424
SiMa GDSC1; GDSC2; CCLE 4.3847 6.4359 2.2526 1.5954
KP-N-SI9s CTRP2; CCLE 4.4948 7.6056 3.7692 13.0463
GI-ME-N GDSC1; GDSC2 4.5053 14.9229 -3.3014 15.8718
Kelly GDSC1; GDSC2; CTRP2; CCLE 4.7831 6.8168 4.4004 9.8085
NB1 GDSC1; GDSC2; CTRP2 4.9329 6.7582 4.5824 8.6947
SK-N-BE(2) CTRP2; CCLE 5.4312 11.4927 2.7938 14.7958
MHH-NB-11 GDSC1; GDSC2; CTRP2 5.5174 10.3496 3.4383 11.9957
CHP-212 GDSC2; CTRP2; CCLE 5.5304 8.4295 4.4004 7.9706
SK-N-FI GDSC1; GDSC2; CTRP2; CCLE 5.5899 8.4603 4.4396 7.6772
KP-N-YS GDSC1; GDSC2 5.8561 7.7576 2.6992 0.4369
SK-N-SH GDSC2; CTRP2; CCLE 6.0393 9.1192 4.5027 6.4899
NH-6 CTRP2 6.6556 9.7757 4.6604 4.7385
SK-N-DZ GDSC1; GDSC2; CTRP2; CCLE 6.7492 11.9832 3.6399 8.8039
CHP-126 GDSC1; GDSC2; CTRP2 6.8953 11.3579 4.0591 6.8338
SJNB-5 GDSC1; GDSC2 7.0028 17.0767 -0.7828 14.3975
SK-N-AS GDSC2; CTRP2; CCLE 7.4891 10.943 4.6689 3.5152
KP-N-YN GDSC1; GDSC2; CTRP2 7.8919 10.0232 5.3024 0.8968
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 -1.2395 2.4396 -1.2821 48.5592
SNU-478 CTRP2 1.7376 9.5206 0.0885 33.6967
SNU-308 CTRP2 1.9088 7.0182 1.232 29.8264
HuCC-T1 GDSC2; CTRP2; CCLE 3.7178 11.3111 1.2878 24.41
SNU-1196 CTRP2 4.9579 12.7483 1.7489 19.8074
HuH-28 CTRP2 6.2586 10.9949 3.7453 9.2462
SNU-869 CTRP2 11.9584 26.8967 0.0387 13.8111
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 92 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-175-VII GDSC2; CCLE 0.6366 4.103 0.0536 22.3827
HCC2157 GDSC1; GDSC2 1.744 5.2044 -0.519 7.6407
UACC-893 GDSC2 2.1982 5.0239 1.4178 15.7643
DU4475 GDSC1; GDSC2 2.2854 3.7157 0.5051 0.8491
CAL-85-1 GDSC2; CTRP2; CCLE 2.2889 9.7039 0.5841 30.6212
Evsa-T GDSC1; GDSC2 2.2978 3.7476 0.498 0.867
MFM-223 GDSC1; GDSC2 2.4134 4.2531 0.3456 1.4253
MRK-nu-1 GDSC1; GDSC2 2.7181 4.2808 0.476 0.6104
AU565 GDSC2; CTRP2; CCLE 2.7797 7.0471 2.1648 23.9289
COLO 824 GDSC1; GDSC2 2.9182 5.5252 0.0653 2.1559
MDA-MB-330 GDSC2 3.0718 6.7196 1.4104 12.8025
SK-BR-3 CTRP2; CCLE 3.0912 5.9609 2.8438 20.5368
UACC-812 GDSC1; GDSC2; CCLE 3.1077 4.835 2.1707 4.1192
OCUB-M GDSC1; GDSC2 3.2375 4.8868 0.4609 0.3729
ZR-75-30 GDSC2; CTRP2; CCLE 3.7562 6.1889 3.5063 16.1233
HCC1954 GDSC2; CTRP2; CCLE 3.8575 8.628 2.6669 19.0332
HCC38 GDSC2 3.8734 5.7099 0.4073 0.2653
BT-474 GDSC1; GDSC2; CTRP2; CCLE 3.9199 6.9 3.4466 15.8663
HCC2218 GDSC1; GDSC2; CTRP2 3.9286 7.1136 3.3754 16.112
HCC1569 GDSC2; CCLE 4.1509 8.2786 1.4959 7.7802
BT-483 GDSC2 4.1653 14.9782 -3.5594 17.5467
HCC70 GDSC2; CCLE 4.2024 9.5293 0.6752 9.548
MDA-MB-415 GDSC2; CCLE 4.2436 6.3571 2.2096 1.9497
MDA-MB-468 GDSC2; CTRP2; CCLE 4.2975 9.4543 2.73 17.661
EFM-19 GDSC2; CCLE 4.3461 6.6935 2.1178 2.2296
HDQ-P1 GDSC2; CTRP2; CCLE 4.3744 14.9146 0.1507 26.2749
MDA-MB-436 GDSC2; CCLE 4.3871 8.3384 1.3795 5.7036
CAL-51 GDSC2; CTRP2 4.7521 8.3397 3.6986 12.6728
HCC1187 GDSC1; GDSC2; CCLE 4.7685 7.1048 2.1667 1.5423
Hs 739.T CCLE 4.9247 7.1707 2.2165 1.2434
HCC1143 GDSC2; CTRP2 5.4181 10.5863 3.2324 13.0523
Hs 578Bst CTRP2 5.42 11.2697 2.8948 14.416
EFM-192A GDSC2; CTRP2 5.4369 9.0747 3.9973 9.8518
MDA-MB-453 GDSC2; CTRP2; CCLE 5.4414 10.8182 3.1381 13.3871
HCC202 CTRP2 5.5329 9.5422 3.8528 10.245
HCC1419 GDSC2; CTRP2 5.5968 9.3968 3.982 9.571
HCC1395 GDSC2; CTRP2; CCLE 5.6856 10.0229 3.7487 10.3573
HCC1599 GDSC1; GDSC2 5.7483 9.9946 1.725 4.6684
CAL-148 GDSC1; GDSC2; CTRP2 6.1121 11.0438 3.6009 10.1227
KPL-1 CTRP2 6.3107 8.4437 5.0588 3.6565
HCC1806 GDSC2; CTRP2; CCLE 6.3612 16.8036 0.9264 19.6747
Hs 578T GDSC2; CTRP2; CCLE 6.502 9.983 4.4423 5.9006
YMB-1-E GDSC2 6.513 8.4546 2.6976 0.2364
BT-20 GDSC2; CTRP2; CCLE 6.588 10.7685 4.1187 7.1004
HCC1500 GDSC2; CTRP2 6.6274 11.3156 3.8775 8.0335
JIMT-1 GDSC2; CTRP2 6.7877 13.0378 3.1462 10.7468
CAL-120 GDSC2; CTRP2 7.0653 11.93 3.903 7.2012
MCF-7 GDSC2; CTRP2; CCLE 7.1458 9.5297 5.1117 2.2352
MDA-MB-231 GDSC2; CTRP2 7.1764 11.154 4.3604 5.1675
MDA-MB-361 GDSC2; CTRP2 7.2691 16.1439 1.9754 14.4013
HMC-1-8 CTRP2; CCLE 7.3841 11.16 4.4984 4.3209
HCC1937 GDSC2; CTRP2 7.4925 14.2324 3.0856 9.8101
MDA-MB-157 GDSC2; CTRP2; CCLE 7.6673 12.5079 4.0446 5.7334
T-47D GDSC2; CTRP2; CCLE 7.714 14.6094 3.061 9.5589
CAMA-1 GDSC2; CTRP2; CCLE 7.883 12.5867 4.1492 5.0322
HCC1428 GDSC2; CTRP2 8.2128 15.6083 2.9267 9.3277
ZR-75-1 CTRP2; CCLE 8.5008 16.7089 2.5945 10.159
BT-549 GDSC2; CTRP2; CCLE 8.5326 10.6456 5.3423 0.4647
BT 239 CTRP2 3.2723 11.2127 0.8985 26.8501
BT 145 CTRP2 3.4258 8.0431 2.4709 20.9459
BT 172 CTRP2 4.0842 11.2634 1.6635 22.1855
BT 416 CTRP2 4.3735 7.8944 3.5185 14.3528
BT 428 CTRP2 4.5544 12.7568 1.3779 22.0378
BT 159 CTRP2 4.7032 14.3809 0.7117 23.8572
BT 271 CTRP2 4.9238 12.752 1.7164 20.0008
BT 245 CTRP2 5.153 8.9969 3.7724 11.4188
BT 139 CTRP2 5.3561 16.0974 0.4334 23.2533
BT 231 CTRP2 5.4202 14.4362 1.3176 20.2983
BT 228 CTRP2 5.8139 13.3278 2.2089 16.2718
BT147 CTRP2 5.8379 11.4469 3.1692 12.4385
BT 330 CTRP2 5.8501 14.5455 1.6308 18.3137
BT 340 CTRP2 6.2513 12.119 3.1777 11.5967
BT 248 CTRP2 6.6211 15.2043 1.9357 15.712
BT 286 CTRP2 6.8975 9.3076 5.0573 2.7626
BT 320 CTRP2 6.9006 12.0778 3.7081 8.2679
BT 359 CTRP2 6.9128 14.8481 2.3437 13.6635
BT164 CTRP2 7.0108 11.4016 4.1223 6.3899
BT 131 CTRP2 7.045 10.7495 4.4645 4.9394
BT 112 CTRP2 7.0737 12.4719 3.6429 8.2493
BT 498 CTRP2 7.1837 8.3707 5.6381 0.4122
BT 187 CTRP2 7.2311 15.5084 2.2614 13.4147
BT 422 CTRP2 7.279 12.6653 3.698 7.6984
BT 482 CTRP2 7.3453 9.1957 5.3753 1.085
BT 444 CTRP2 7.4145 12.0066 4.1134 5.8168
BT 232 CTRP2 7.6616 15.787 2.4463 12.0012
BT 440 CTRP2 7.6659 12.2976 4.144 5.3418
BT 216 CTRP2 7.6674 14.1795 3.2373 8.9389
BT 504 CTRP2 7.7657 13.404 3.6815 7.035
BT 328 CTRP2 7.7986 13.088 3.8555 6.2998
BT 179 CTRP2 8.2444 16.5986 2.4694 11.0022
BT 224 CTRP2 8.5923 14.5685 3.6724 5.9634
BT 333 CTRP2 9.7733 17.2241 3.1717 6.4035
⏷ Show the Full List of 92 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 -0.6459 5.1071 -1.024 45.1644
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PFSK-1 GDSC2 1.979 5.2915 -0.3948 6.3475
AM-38 GDSC1; GDSC2 2.4132 4.3537 0.3029 1.6298
LN-405 GDSC2 2.5905 4.7605 0.2214 1.8052
D-263MG GDSC1; GDSC2 2.9783 4.9822 0.3172 0.9903
SK-MG-1 GDSC2 3.1112 5.1405 0.314 0.8975
KINGS-1 GDSC1; GDSC2 3.1736 5.1583 0.3341 0.7824
D-392MG GDSC1; GDSC2 3.1905 9.6012 -1.6405 10.869
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 3.3393 12.4633 -2.9184 16.6791
MOG-G-UVW GDSC2 3.3482 5.3687 0.3275 0.6913
D-566MG GDSC2 3.6294 6.0373 2.2112 6.1867
SNU-466 CTRP2 3.7641 7.0161 3.2363 17.1038
H4 GDSC2; CCLE 3.8242 8.1942 1.0537 8.405
D-336MG GDSC1; GDSC2 3.9254 6.4652 2.2204 5.2154
Onda 10 GDSC1; GDSC2 4.2091 6.0865 2.5904 2.5093
1321N1 CCLE 4.2346 8.5433 1.1776 7.1695
D-247MG GDSC1; GDSC2 4.4452 11.2913 0.2303 15.2128
Onda 11 GDSC1; GDSC2 4.644 10.9641 0.5388 13.1591
GI-1 GDSC1; GDSC2; CCLE 4.7268 6.9607 2.2063 1.4279
U-87MG ATCC GDSC1; GDSC2; CCLE 4.7414 6.2539 2.496 0.441
D-423MG GDSC2 4.7524 8.7889 1.669 6.9267
M059J GDSC2; CCLE 5.133 7.6908 2.1035 1.4443
DBTRG-05MG GDSC2; CTRP2; CCLE 5.2336 9.1591 3.7687 11.2508
NMC-G1 GDSC1; GDSC2; CTRP2 5.3327 10.7328 3.0835 13.8426
KG-1-C CTRP2 5.3863 9.9745 3.5071 11.9927
KNS-81-FD GDSC1; GDSC2 5.5598 7.4537 2.6929 0.6004
MOG-G-CCM GDSC2; CCLE 5.5669 7.7384 2.2789 0.5932
GB-1 GDSC1; GDSC2; CTRP2; CCLE 5.6853 11.2025 3.1603 12.7854
D-502MG GDSC1; GDSC2 5.6999 21.656 -3.9466 26.9009
SNU-489 CTRP2 5.7422 8.9486 4.3333 7.7973
D-245MG GDSC2 5.7824 9.9344 1.7712 4.5355
SNB-75 GDSC1; GDSC2; CTRP2 5.7976 11.1508 3.2827 12.056
D283 Med GDSC1; GDSC2; CTRP2 5.8383 9.6453 4.0694 8.7059
KALS-1 GDSC1; GDSC2; CTRP2; CCLE 5.9621 11.8412 3.0771 12.5652
SNU-626 CTRP2 6.0085 8.0859 4.9935 4.4869
SNU-1105 CTRP2 6.084 9.7302 4.2344 7.5305
SNU-201 CTRP2 6.1808 10.6382 3.8602 8.9132
Daoy GDSC2; CTRP2; CCLE 6.3008 11.351 3.6016 9.7637
SF539 GDSC1; GDSC2; CTRP2 6.4182 12.733 3.0062 11.9767
KNS-60 CTRP2; CCLE 6.4322 9.2483 4.7531 4.7239
SNU-738 CTRP2 6.4532 10.3205 4.2367 6.8433
SW1088 GDSC2; CTRP2; CCLE 6.4804 10.4911 4.1731 7.0607
KNS-81 CTRP2; CCLE 6.5103 10.1508 4.3654 6.2069
SF126 GDSC1; GDSC2; CTRP2; CCLE 6.5478 9.7187 4.608 5.1328
SF268 GDSC1; GDSC2; CTRP2 6.5731 12.2975 3.3468 10.3144
CAS-1 GDSC1; GDSC2; CTRP2; CCLE 6.6034 8.428 5.2801 2.2803
DK-MG GDSC2; CTRP2; CCLE 6.6357 11.6015 3.7419 8.5802
TM-31 CTRP2 6.7168 10.1917 4.5009 5.2991
LN-229 GDSC2; CTRP2; CCLE 6.7417 14.251 2.5067 13.3489
YH-13 GDSC2; CTRP2 6.8553 9.4441 4.9636 3.1956
U-118MG GDSC2; CTRP2; CCLE 6.8833 11.8157 3.8246 7.8183
Hs 683 GDSC2; CTRP2; CCLE 6.9625 9.5012 5.0083 2.8692
M059K CTRP2 7.0093 8.9801 5.2814 1.7535
42-MG-BA GDSC2; CTRP2; CCLE 7.0838 12.1394 3.8138 7.5362
ONS-76 GDSC1; GDSC2; CTRP2; CCLE 7.1494 10.2288 4.7859 3.4984
GOS-3 CTRP2 7.1521 11.1425 4.349 5.2493
8-MG-BA GDSC1; GDSC2; CTRP2; CCLE 7.2196 11.8032 4.0759 6.2567
SF295 GDSC2; CTRP2; CCLE 7.2501 9.5974 5.1437 1.9947
CCF-STTG1 CTRP2 7.3494 8.4772 5.6688 0.2589
GaMG GDSC2; CTRP2; CCLE 7.4361 11.8395 4.2086 5.404
GMS-10 CTRP2; CCLE 7.5323 10.805 4.7602 3.1113
T98G GDSC2; CTRP2; CCLE 7.761 12.5682 4.0783 5.472
D-542MG GDSC1; GDSC2 7.7737 23.4676 -3.3254 21.4713
KNS-42 GDSC1; GDSC2; CTRP2; CCLE 7.785 13.4783 3.659 7.0964
A-172 GDSC2; CTRP2; CCLE 7.8243 12.3921 4.203 4.8988
YKG-1 GDSC2; CTRP2; CCLE 8.1256 14.1448 3.5698 6.9684
Becker GDSC1; GDSC2; CTRP2 8.2368 15.5931 2.9506 9.2018
SW1783 GDSC2; CTRP2 8.8241 10.5656 5.4832 0.156
LN-18 GDSC2; CTRP2; CCLE 10.9896 22.8648 1.3116 11.2425
U-251MG GDSC2; CTRP2 12.96 25.8249 1.1501 9.53
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 1.2012 7.2869 -1.9774 17.5754
TGBC1TKB GDSC1; GDSC2 2.5835 4.1377 0.473 0.7191
ETK-1 GDSC1; GDSC2 3.4152 12.8829 -3.0688 17.1527
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 GDSC1; GDSC2; CTRP2; CCLE 2.3542 7.1142 1.6815 26.9213
JHUEM-3 CTRP2 3.1362 6.4113 2.7633 20.6913
JHUEM-2 CTRP2; CCLE 3.1942 4.895 3.1561 19.1169
MFE-280 GDSC2; CCLE 3.4496 6.9563 1.383 7.4928
HEC-1-B CTRP2; CCLE 3.8514 10.931 1.5978 23.0057
JHUEM-7 CTRP2 4.1949 6.5692 3.8617 13.5166
HEC-251 CTRP2; CCLE 4.1994 9.1437 2.7777 17.7202
AN3-CA GDSC2; CTRP2; CCLE 4.6337 8.1505 3.6678 13.0917
MFE-296 GDSC2; CTRP2; CCLE 4.8982 9.652 3.2146 14.2851
HEC-151 CTRP2; CCLE 5.0005 13.7405 1.2951 21.2938
TEN CCLE 5.1108 7.3174 2.2443 0.9946
JHUEM-1 CTRP2 5.1799 9.3131 3.6435 11.8876
HEC-1-A CTRP2; CCLE 5.244 8.9049 3.9024 10.6754
HEC-59 CTRP2; CCLE 5.6597 9.251 4.1102 8.9029
HEC-6 CTRP2; CCLE 6.1531 10.1974 4.0578 8.1397
ESS-1 GDSC2; CTRP2; CCLE 6.6567 8.5233 5.2706 2.2433
HEC-265 CTRP2; CCLE 6.721 9.4695 4.8578 3.8235
KLE GDSC2; CTRP2; CCLE 6.9841 12.7379 3.4449 9.2021
EN GDSC2; CTRP2; CCLE 7.368 9.2152 5.3788 1.0543
EFE-184 CTRP2; CCLE 8.7253 19.8603 1.2232 14.6261
HEC-108 CTRP2 8.8033 19.2804 1.5608 13.3849
MFE-319 GDSC2; CTRP2; CCLE 9.3765 22.9608 0.1767 16.861
HEC-50B CTRP2 10.6012 29.5635 -2.1678 20.9871
Ishikawa (Heraklio) 02 ER- CTRP2; CCLE 7.5527 21.236 -0.3339 21.2113
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB996-RCC GDSC1; GDSC2 0.1078 14.3685 -6.4415 35.3925
TK-10 GDSC1; GDSC2 0.4305 5.8276 -1.9035 19.5768
SW13 GDSC2 1.0193 6.0889 -1.5284 15.6485
CAL-54 GDSC2; CTRP2 1.2812 13.0503 -1.932 39.1047
SN12C GDSC2 2.2424 8.5343 -1.7885 13.7872
A-704 GDSC2 2.2564 9.3708 -2.1901 15.8261
KTCTL-195 GDSC2 2.4676 4.837 0.1225 2.4698
LB1047-RCC GDSC1; GDSC2 2.7056 9.4679 -0.2787 22.5553
KTCTL-13 GDSC2 3.0598 5.7821 1.8671 9.998
LB2241-RCC GDSC1; GDSC2 3.2071 16.8112 -3.5186 31.5849
SW156 GDSC2 3.2285 10.7676 -0.4791 22.4527
UO-31 GDSC2; CTRP2 3.2522 10.3905 1.2593 25.7453
KTCTL-140 GDSC2 3.9445 13.6092 -1.3126 23.7754
HA7-RCC GDSC1; GDSC2 4.1619 10.9776 0.1696 16.2249
KTCTL-21 GDSC2 4.3459 13.6942 -1.0375 21.6547
RXF 393L GDSC1; GDSC2 4.4627 10.0297 0.8647 11.8403
KTCTL-26A GDSC2 4.5041 10.8102 0.5115 14.0521
NCC021 GDSC2 4.5419 8.994 1.427 8.7996
KTCTL-1M GDSC2 4.6025 10.9284 0.526 13.7339
NCC010 GDSC2 5.1608 13.1473 -0.1553 15.8197
ACHN GDSC2; CTRP2; CCLE 5.1759 14.6301 1.0079 21.8563
TUHR4TKB CTRP2 5.2368 9.7408 3.4864 12.4063
VMRC-RCW GDSC2; CTRP2; CCLE 5.4643 8.7381 4.1881 8.9991
Caki-2 CTRP2; CCLE 5.5642 11.8961 2.7093 14.85
BB65-RCC GDSC1; GDSC2 5.6176 16.2269 -1.3317 19.3048
KMRC-3 CTRP2 5.7796 15.8107 0.9389 20.7966
769-P GDSC2; CTRP2; CCLE 5.8156 17.3933 0.1782 23.0412
BFTC-909 GDSC2; CTRP2; CCLE 6.3427 10.6689 3.9758 8.1309
OS-RC-2 GDSC1; GDSC2; CTRP2 6.6406 14.8008 2.1526 14.8764
KMRC-1 GDSC2; CTRP2; CCLE 6.6947 11.3173 3.9283 7.7075
A-498 GDSC2; CTRP2 6.8675 10.4551 4.4817 5.1395
786-O GDSC2; CTRP2; CCLE 7.1318 11.4288 4.1958 5.9025
TUHR10TKB CTRP2 7.1605 9.7512 5.018 2.5758
Caki-1 GDSC2; CTRP2 7.4047 17.2497 1.5311 15.7391
VMRC-RCZ GDSC2; CTRP2; CCLE 8.0924 18.0663 1.6431 14.2055
SNU-1272 CTRP2 8.2098 13.3259 4.0112 5.1495
TUHR14TKB CTRP2 8.3554 13.4751 4.0329 4.8879
KMRC-20 GDSC2; CTRP2 8.6849 17.6066 2.2885 11.0122
KMRC-2 CTRP2; CCLE 10.1829 19.1744 2.5241 8.2056
RCC10RGB GDSC1; GDSC2; CTRP2 12.6303 26.5204 0.6355 11.3662
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DiFi GDSC2 -1.9293 2.7432 -2.7978 33.429
CCK-81 GDSC2; CTRP2; CCLE 0.3928 5.2905 0.065 38.5626
NCI-H508 GDSC2; CTRP2 1.1583 7.4974 0.2549 35.2291
SW48 GDSC2; CTRP2; CCLE 1.3484 10.9907 -0.9438 37.2447
SW1116 GDSC2; CTRP2 1.434 7.6785 0.4881 33.6474
SNU-175 GDSC2 1.5263 7.6164 -1.8805 16.1395
HT115 GDSC2; CTRP2 1.667 6.1167 1.2472 30.5629
LoVo GDSC2; CTRP2 1.796 5.6631 1.5063 29.2824
CaR-1 GDSC2 1.9412 4.9666 -0.2643 5.6419
SW403 CCLE 2.4471 6.8511 0.5962 14.4015
GP2d CTRP2 2.5152 10.601 0.4212 30.4068
SW626 GDSC2 2.5517 5.7892 -0.2582 4.4187
SW837 GDSC2 2.8724 6.7327 -0.497 5.198
HT-55 GDSC2; CTRP2 2.8997 10.1682 1.0053 27.5503
GP5d GDSC2 2.9086 7.6711 -0.9107 7.4528
COLO 320HSR GDSC1; GDSC2 3.008 4.7066 0.4359 0.5573
SW1463 GDSC2 3.7086 15.4272 -4.0997 20.4602
COLO 678 GDSC2; CTRP2; CCLE 3.8803 10.2757 1.9352 21.7263
HCT 15 GDSC2; CTRP2; CCLE 4.0231 7.9374 3.1385 16.7667
SNU-407 GDSC2; CTRP2 4.0291 7.9956 3.1197 16.8238
CW-2 GDSC1; GDSC2; CTRP2 4.0344 7.4795 3.3422 15.9463
HCC2998 GDSC1; GDSC2 4.0928 6.497 0.2097 0.6315
SNU-61 GDSC2; CTRP2 4.161 9.5494 2.5512 18.6974
T84 GDSC2; CTRP2; CCLE 4.2205 9.1434 2.7988 17.5844
LS180 GDSC2; CTRP2 4.3615 10.1253 2.4747 18.495
NCI-H747 GDSC1; GDSC2; CTRP2; CCLE 4.486 15.6545 -0.1141 26.7404
SNU-283 GDSC2 4.5003 11.8806 -0.0195 16.7675
SNU-C2B GDSC2; CCLE 4.6132 10.3938 0.5459 9.3915
SNU-81 GDSC2 4.8248 8.7978 1.7123 6.5287
COLO 320 CTRP2; CCLE 4.9837 10.4458 2.9074 15.3264
SNU-1033 CTRP2 5.0681 13.9245 1.2639 21.2482
NCI-H716 GDSC1; GDSC2; CTRP2 5.2063 7.9727 4.3161 9.0623
SNU-C4 CTRP2 5.2465 12.6382 2.061 18.0246
SK-CO-1 GDSC2; CTRP2; CCLE 5.4514 12.4581 2.3309 16.5628
MDST8 GDSC1; GDSC2; CTRP2 5.5771 8.6989 4.3101 8.2445
COLO201 CTRP2; CCLE 5.6358 9.807 3.8126 10.1952
SW620 GDSC2; CTRP2; CCLE 5.7247 9.4294 4.0787 8.8993
CL-11 GDSC1; GDSC2; CTRP2 5.8342 8.9963 4.3898 7.3713
OUMS-23 CTRP2 5.8499 9.8645 3.9699 9.0989
SW480 CCLE 6.0966 9.7037 1.7421 1.9887
DLD-1 CTRP2 6.1093 8.1903 5.025 4.161
SNU-C5 GDSC2; CTRP2 6.2765 10.5671 3.9735 8.2618
SNU-C2A CTRP2; CCLE 6.3201 11.1761 3.7045 9.3013
SW1417 GDSC2; CTRP2; CCLE 6.3786 10.0098 4.3329 6.5735
SW948 GDSC2; CTRP2 6.525 8.7089 5.0883 3.1807
HT-29 GDSC2; CTRP2; CCLE 6.603 8.001 5.4832 1.4733
C2BBe1 GDSC1; GDSC2; CTRP2; CCLE 6.6658 14.7882 2.179 14.7311
SNU-C1 GDSC1; GDSC2; CTRP2 6.7738 11.814 3.7426 8.3397
LS123 GDSC1; GDSC2; CTRP2; CCLE 6.8607 12.8143 3.3134 9.9448
SNU-503 CTRP2 7.1834 17.1338 1.4179 16.5155
RKO GDSC1; GDSC2; CTRP2; CCLE 7.3679 10.2619 4.91 2.7375
HCT 8 CTRP2 7.3983 12.7712 3.7317 7.3781
LS1034 GDSC1; GDSC2; CTRP2 7.7859 9.173 5.5871 0.2585
LS411N GDSC1; GDSC2; CTRP2; CCLE 7.9859 9.3662 5.5948 0.1861
RCM-1 [Human ESC] GDSC2; CTRP2 8.6072 20.3841 0.882 15.9043
HCT 116 GDSC2; CTRP2; CCLE 9.2608 20.5256 1.2775 13.6519
HCC-56 CTRP2; CCLE 9.262 19.2415 1.8966 11.5732
COLO205 GDSC2; CTRP2; CCLE 9.9883 20.211 1.9165 10.5289
LS513 GDSC1; CTRP2; CCLE 10.5803 24.2716 0.3776 14.5917
KM12 GDSC1; GDSC2; CTRP2 12.5419 25.4981 1.0509 10.2587
⏷ Show the Full List of 60 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 3.7794 5.5958 0.4128 0.2826
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-5 CTRP2; CCLE 2.3647 9.6516 0.6851 30.097
Huh-7 GDSC2 2.7837 8.7263 -1.4966 10.9621
JHH-7 GDSC2; CCLE 2.9993 5.0999 1.9495 5.541
Hep-G2/C3A GDSC2; CCLE 3.2423 4.7785 2.3037 3.125
SNU-878 CTRP2 3.5488 6.9665 3.0232 18.5206
HLE GDSC2; CCLE 3.5548 7.1713 1.3567 7.4043
SNU-182 CTRP2; CCLE 4.4474 8.4987 3.3219 14.9435
HuH-6 CTRP2 4.7432 9.464 3.1579 14.878
JHH-4 GDSC2; CTRP2; CCLE 5.0925 10.9804 2.7442 15.7317
Li-7 CTRP2 5.3046 11.3783 2.7383 15.2884
JHH-1 GDSC2; CTRP2 5.7432 12.4107 2.6069 14.8828
SNU-761 CTRP2 6.1295 13.3689 2.4528 14.7098
SK-HEP-1 GDSC2; CTRP2; CCLE 6.6734 11.9448 3.6006 9.0967
SNU-423 GDSC2; CTRP2; CCLE 7.1027 10.3178 4.7123 3.8556
SNU-475 CTRP2; CCLE 7.1674 10.4099 4.7117 3.7688
PLC/PRF/5 CTRP2; CCLE 7.3216 11.9331 4.0845 6.0691
JHH-2 GDSC2; CTRP2; CCLE 7.3783 12.7838 3.7113 7.4911
JHH-6 GDSC2; CTRP2; CCLE 7.3905 8.2062 5.7821 0.065
Hep 3B2.1-7 GDSC2; CTRP2; CCLE 7.4169 14.9034 2.7002 11.435
HuH-1 GDSC2; CTRP2; CCLE 7.4848 13.9756 3.2057 9.3477
SNU-398 GDSC2; CTRP2; CCLE 7.5575 9.3841 5.4034 0.8316
HLF CTRP2; CCLE 7.8571 11.7125 4.5408 3.5585
SNU-886 CTRP2 7.9095 10.2753 5.2068 1.1683
Hep-G2 CTRP2; CCLE 8.2889 21.796 -0.048 19.1878
SNU-387 GDSC2; CTRP2; CCLE 8.3556 10.1126 5.4682 0.288
SNU-449 GDSC2; CTRP2; CCLE 8.5462 15.7036 3.107 8.1708
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 226 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC827 GDSC2; CTRP2; CCLE -4.7784 1.3171 -4.8884 68.7821
PC-14 GDSC2; CTRP2; CCLE -3.8619 4.1035 -4.3053 62.2333
HCC4006 CTRP2; CCLE -3.2314 0.4198 -3.2439 61.4926
PaCa-3 GDSC2 -2.276 6.5096 -4.8032 40.6243
NCI-H3255 GDSC2; CCLE -1.9369 2.497 -2.2148 44.5532
HCC2935 CTRP2; CCLE -1.3206 5.0341 -1.7416 49.1964
NCI-H1648 GDSC1; GDSC2; CCLE -0.7919 6.6298 -2.4852 37.2397
RERF-LC-Sq1 GDSC2 0.0819 8.4094 -3.4951 27.9034
NCI-H322 CTRP2; CCLE 0.0997 5.9394 -0.4148 40.8259
COR-L105 GDSC2; CTRP2; CCLE 0.2109 5.0215 -0.0746 39.6268
NCI-H1666 GDSC1; GDSC2; CTRP2; CCLE 0.2897 7.6858 -0.75 40.6783
NCI-H1623 GDSC2; CTRP2 0.6487 4.383 0.5122 36.3714
NCI-H358 GDSC2; CTRP2; CCLE 0.8443 5.8627 0.418 35.9239
NCI-H322M GDSC1; GDSC2 1.0922 9.6184 -3.2326 23.7194
DMS 454 CTRP2 1.1746 3.4287 -2.6788 0.6823
LC-1/sq GDSC2 1.2047 10.5738 -3.6174 24.8759
NCI-H209 GDSC1; GDSC2 1.2915 3.5188 -0.0255 5.6928
NCI-H2795 GDSC2 1.3816 5.8387 -1.1091 12.1614
NCI-H1781 GDSC2 1.6269 6.9605 -1.4753 13.6335
NCI-H513 GDSC2 1.6998 8.3236 -2.0962 16.7937
NCI-H2818 GDSC2 1.8476 5.325 -0.5033 7.3013
Calu-3 GDSC2; CTRP2; CCLE 1.8698 5.9745 1.5074 29.0395
NCI-H2722 GDSC2 1.9038 6.451 -1.0139 10.2431
UMC-11 GDSC2 1.9295 12.9753 -4.2317 25.0502
NCI-H2066 GDSC2 1.9464 6.3647 -0.9403 9.7036
EMC-BAC-2 GDSC2 2.0978 7.6591 -1.4648 12.3706
NCI-H2170 GDSC2; CTRP2; CCLE 2.1624 7.6409 1.2853 28.8495
Ms-1 GDSC1; GDSC2 2.174 4.2522 0.2168 2.4095
NCI-H1688 GDSC2 2.1786 8.6381 -1.8868 14.4652
NCI-H2369 GDSC2 2.189 6.578 -0.871 8.7282
NCI-H720 GDSC1; GDSC2 2.1978 3.3979 0.5917 0.5798
NCI-H1304 GDSC1 2.2631 3.808 0.4566 1.3489
COR-L279 GDSC2 2.2863 4.8012 0.0343 3.232
NCI-H596 GDSC2 2.3157 4.2366 0.302 1.759
NCI-H847 GDSC1; GDSC2 2.421 5.2246 -0.0784 3.6342
NCI-H1568 GDSC2; CTRP2; CCLE 2.4223 7.793 1.5066 27.3117
NCI-H2347 GDSC2 2.4304 4.7346 0.147 2.3953
EPLC-272H GDSC2; CTRP2 2.4593 8.8227 1.1346 28.4276
EMC-BAC-1 GDSC2 2.5304 8.9784 -0.1903 23.3857
NCI-H1573 GDSC2; CTRP2; CCLE 2.5432 10.3161 0.5769 29.8802
NCI-H835 GDSC2 2.5799 5.4665 -0.0944 3.4608
NCI-H2141 GDSC1; GDSC2 2.5859 8.4964 -1.5229 11.5436
CPC-N GDSC1; GDSC2 2.5915 5.0526 0.0959 2.4311
NCI-H187 GDSC1 2.6161 4.1778 0.4717 0.8704
Lu-99A GDSC2 2.632 6.5314 -0.5527 5.9497
NCI-H1975 GDSC1; GDSC2; CTRP2; CCLE 2.6446 5.9162 2.3683 23.6087
NCI-H1963 GDSC1; GDSC2 2.6453 4.7189 0.2667 1.5266
NCI-H1734 GDSC2; CTRP2 2.6645 5.7922 2.4215 23.3588
COR-L311 GDSC2 2.6833 4.7987 0.2523 1.5501
EKVX GDSC1; GDSC2; CTRP2 2.7216 16.6828 -2.2464 35.5981
Lu-165 GDSC1; GDSC2 2.7474 4.1012 0.5551 0.3525
NCI-H82 GDSC1; GDSC2 2.767 9.6383 -1.9499 13.3946
NCI-H524 GDSC1; GDSC2 2.768 5.6007 -0.0476 2.9244
LK-2 GDSC2 2.8053 4.7496 0.3309 1.0853
NCI-H64 GDSC1; GDSC2 2.8063 3.9969 0.6148 0.1906
NCI-H1876 GDSC1; GDSC2 2.904 7.3979 -0.7855 6.7582
Calu-6 GDSC1; GDSC2; CTRP2; CCLE 2.9954 4.4863 2.9804 20.3629
NCI-H1993 GDSC2 3.0065 4.8768 0.3706 0.7728
NCI-H2373 GDSC2 3.0339 6.2748 -0.1973 3.3205
NCI-H2591 GDSC2 3.0442 8.0075 -0.9819 7.5899
CAL-12T GDSC2; CTRP2; CCLE 3.0901 15.9293 -1.5339 33.3994
NCI-H2595 GDSC2 3.1637 5.192 0.3169 0.8488
RERF-LC-KJ GDSC2 3.1642 13.284 -3.445 19.2356
SBC-3 GDSC2 3.1861 5.6385 0.1503 1.4777
SK-MES-1 GDSC2; CTRP2; CCLE 3.1874 9.6128 1.5461 24.9556
LC-2/ad GDSC1; GDSC2 3.2289 9.6751 0.0675 19.2987
NCI-H2461 GDSC2 3.2367 11.5336 -2.5393 15.2132
NCI-H1869 GDSC1; GDSC2; CTRP2; CCLE 3.2468 12.4038 0.3123 28.6556
NCI-H128 GDSC1 3.2527 4.7203 0.5257 0.2815
Lu-135 GDSC2 3.3804 5.2679 0.3781 0.5234
NCI-H1435 GDSC2; CTRP2 3.4284 8.613 2.2326 21.8288
Sq-1 CTRP2; CCLE 3.5357 7.2114 2.9182 18.9527
DV-90 CTRP2; CCLE 3.5816 8.5749 2.4071 20.7596
NCI-H1651 GDSC2; CCLE 3.6011 6.5583 1.6936 5.562
NCI-H1048 GDSC2; CCLE 3.6035 5.5226 2.1993 2.9651
NCI-H2731 GDSC2 3.6327 5.8411 0.2674 0.7091
NCI-H3122 GDSC2 3.6563 5.7351 0.3161 0.5563
Lu-139 GDSC1 3.6703 5.4321 0.43 0.3524
LCLC-97TM1 GDSC2; CTRP2 3.7096 7.5529 2.9698 18.2694
IST-SL2 GDSC1; GDSC2 3.7508 6.7827 1.9346 6.1733
NCI-H2227 GDSC1; GDSC2 3.7612 7.594 1.5401 9.684
NCI-H1755 GDSC2; CTRP2 3.7793 8.1678 2.787 18.7796
COLO 677 CCLE 3.9614 6.2432 2.0925 2.9768
Lu-134-A GDSC1; GDSC2 3.9967 6.067 2.4629 3.6316
NCI-H1355 GDSC1; GDSC2; CTRP2; CCLE 4.0308 10.0325 2.1969 20.3747
NCI-H2171 GDSC1; GDSC2 4.0459 6.1218 2.4696 3.4937
NCI-H1437 GDSC2 4.125 7.4206 1.8972 6.9254
COR-L23 GDSC2; CCLE 4.1597 8.0364 1.3705 6.1489
NCI-H1581 GDSC1; GDSC2; CTRP2; CCLE 4.1678 7.448 3.4953 14.9909
NCI-H345 GDSC1; GDSC2 4.2351 5.2639 2.9652 0.6035
GLC-82 CCLE 4.2875 9.3599 0.8187 8.9021
A-427 GDSC2 4.2923 6.9779 2.2257 4.5732
NCI-H661 GDSC2; CTRP2; CCLE 4.3651 10.6205 2.241 19.3788
NCI-H2810 GDSC2 4.3652 10.0704 0.7728 12.9757
NCI-H2030 GDSC2; CTRP2; CCLE 4.3703 11.124 2.003 20.2553
COR-L321 GDSC2 4.3857 8.1707 1.7166 7.4276
NCI-H2804 GDSC2 4.4033 8.571 1.5349 8.4748
NCI-H2286 CTRP2; CCLE 4.4487 9.036 3.0745 15.9258
NCI-H1944 GDSC2; CTRP2; CCLE 4.4589 15.1401 0.1159 26.1742
SW900 CCLE 4.4609 6.8193 2.1265 2.104
SK-LU-1 GDSC2; CTRP2; CCLE 4.4661 8.2155 3.4697 14.3074
NCI-H1563 GDSC2; CTRP2; CCLE 4.5118 10.8657 2.2618 18.9463
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2; CCLE 4.5735 10.4529 2.5199 17.8087
NCI-H2228 GDSC2; CTRP2; CCLE 4.6122 9.3416 3.0901 15.4637
NCI-H2405 GDSC2; CTRP2 4.6812 8.6045 3.5052 13.627
NCI-H2110 GDSC2; CTRP2 4.7166 10.9425 2.4166 17.871
NCI-H1838 GDSC1; GDSC2; CTRP2 4.7278 10.8567 2.4689 17.6426
NCI-H2803 GDSC2 4.7355 8.2304 1.922 5.4855
IST-SL1 GDSC1; GDSC2 4.7375 7.6456 2.1949 3.7815
NCI-H1373 CTRP2; CCLE 4.8198 7.8439 3.9944 11.3136
LB647-SCLC GDSC1; GDSC2 4.9197 8.2415 2.0318 4.3631
DMS 53 GDSC2; CTRP2 4.9312 11.0999 2.538 16.9058
HCC1171 CTRP2 4.9322 10.6426 2.7633 16.0176
NCI-H1693 GDSC2; CTRP2; CCLE 5.0074 12.916 1.7102 19.8346
Lu-65 GDSC1; GDSC2; CTRP2 5.0367 9.5646 3.3873 13.2636
NCI-H290 GDSC2 5.0416 13.5427 -0.4358 17.3851
HCC2108 CTRP2 5.1005 9.2107 3.6192 12.1682
SBC-1 GDSC1; GDSC2 5.1019 6.7829 2.7552 0.6904
NCI-H2135 GDSC1; GDSC2 5.1405 6.9068 2.7239 0.7713
NCI-H1184 CTRP2; CCLE 5.2602 9.6791 3.5383 12.1407
LUDLU-1 CTRP2; CCLE 5.2919 11.6992 2.5678 15.9883
NCI-H2009 GDSC2; CTRP2; CCLE 5.3394 11.7752 2.5722 15.8682
HCC15 GDSC2; CTRP2; CCLE 5.3518 9.6374 3.6425 11.509
NCI-H650 GDSC2; CTRP2; CCLE 5.365 8.794 4.0692 9.7129
COR-L303 GDSC2 5.4196 7.0356 2.7912 0.4142
NCI-H146 GDSC2; CTRP2 5.4307 9.683 3.6913 11.1353
NCI-H250 GDSC2 5.4554 7.6114 2.5876 1.0602
NCI-H1703 GDSC2; CTRP2; CCLE 5.4642 9.3458 3.8884 10.2449
HCC95 CTRP2 5.4729 13.2962 1.9319 18.0144
HOP-92 GDSC2; CTRP2 5.4889 13.5387 1.8248 18.3711
Lu-99 CTRP2; CCLE 5.4986 10.9 3.148 13.2251
NCI-H740 GDSC2 5.5303 9.1504 1.9773 3.8339
HCC33 GDSC1; GDSC2 5.5636 7.0399 2.8444 0.2275
NCI-H2085 GDSC2; CTRP2; CCLE 5.571 11.8252 2.7506 14.6724
NCI-H292 GDSC2; CTRP2 5.5921 18.0019 -0.3153 24.8632
NCI-H69 GDSC1; GDSC2; CTRP2 5.5949 9.6241 3.8674 10.0528
COR-L32 GDSC2 5.6099 7.6621 2.6351 0.6294
NCI-H510A GDSC1; GDSC2 5.7071 7.334 2.7941 0.2807
NCI-H748 GDSC1; GDSC2 5.712 7.6055 2.6981 0.5058
EBC-1 GDSC2; CTRP2; CCLE 5.7535 9.1639 4.236 8.1813
ABC-1 GDSC2 5.7603 8.2668 2.4659 1.276
NCI-H1836 GDSC1; GDSC2 5.7652 7.3607 2.8062 0.2391
RERF-LC-MS GDSC2; CTRP2; CCLE 5.7838 9.3997 4.145 8.5002
NCI-H2869 GDSC2 5.8659 8.2841 2.5058 1.0436
NCI-H1770 GDSC1; GDSC2 5.8719 7.153 2.9141 0.0708
NCI-H1436 GDSC1; GDSC2 5.9313 7.4879 2.822 0.1704
KNS-62 GDSC2; CTRP2; CCLE 5.9465 11.2224 3.3733 11.3857
NCI-H446 GDSC1; GDSC2; CTRP2 5.9536 10.7323 3.6244 10.3335
Hs 229.T CCLE 6.018 8.4551 2.1953 0.6071
HCC44 GDSC2; CTRP2; CCLE 6.0295 9.9003 4.104 8.1824
NCI-H841 GDSC2; CTRP2 6.03 13.0895 2.5098 14.6847
COR-L47 CTRP2 6.0342 9.1772 4.4695 6.6392
VMRC-LCD GDSC2; CTRP2; CCLE 6.0374 9.3948 4.3633 7.0791
NCI-H1155 GDSC1; GDSC2; CTRP2; CCLE 6.055 11.2332 3.4588 10.8212
COLO 699 CTRP2; CCLE 6.0647 9.7832 4.1919 7.7458
NCI-H1650 GDSC1; GDSC2; CTRP2; CCLE 6.0795 16.0609 1.0654 19.7774
RERF-LC-A1 CTRP2; CCLE 6.1858 11.2574 3.5547 10.1736
DMS 79 GDSC1; GDSC2 6.2269 15.7263 -0.658 15.3609
NCI-H2122 GDSC2; CTRP2; CCLE 6.2588 20.161 -0.8361 24.8713
DMS 114 GDSC1; GDSC2; CTRP2; CCLE 6.2652 9.239 4.6272 5.5443
IA-LM GDSC2; CTRP2; CCLE 6.288 8.7264 4.9006 4.358
Calu-1 CTRP2; CCLE 6.3764 11.933 3.372 10.5696
LOU-NH91 GDSC2; CTRP2; CCLE 6.422 16.8808 0.9376 19.5209
NCI-H1339 CTRP2; CCLE 6.4235 8.7248 5.0055 3.6874
RERF-LC-Ad1 CTRP2 6.4349 8.7961 4.9788 3.7795
NCI-H1915 GDSC2; CTRP2; CCLE 6.4392 12.6549 3.0621 11.7128
NCI-H1793 GDSC2; CTRP2; CCLE 6.4474 16.8918 0.9528 19.4233
NCI-H1341 GDSC2; CTRP2; CCLE 6.4644 11.3473 3.7344 8.9148
NCI-H1694 GDSC1; GDSC2; CTRP2; CCLE 6.4687 9.6841 4.5649 5.4461
NCI-H2291 GDSC2; CTRP2 6.482 11.9936 3.4262 10.1538
LK2 CTRP2 6.5144 7.9547 5.4468 1.7364
COR-L88 GDSC1; GDSC2; CTRP2 6.5346 11.8806 3.5241 9.6569
NCI-H1792 GDSC2; CTRP2; CCLE 6.5862 12.4542 3.2791 10.5665
A-549 GDSC2; CTRP2; CCLE 6.6186 13.3098 2.8785 12.1187
NCI-H647 GDSC2; CTRP2; CCLE 6.6193 10.8141 4.1201 7.0412
NCI-H196 GDSC2; CTRP2 6.6475 10.0929 4.4982 5.4234
SW1271 GDSC2; CTRP2; CCLE 6.6693 9.6829 4.716 4.487
NCI-H211 GDSC1; GDSC2; CTRP2; CCLE 6.6879 9.1255 5.0016 3.286
HOP-62 GDSC1; GDSC2; CTRP2 6.7464 16.6935 1.293 17.734
NCI-H526 GDSC1; GDSC2; CTRP2 6.8523 10.2995 4.5468 4.8959
LXF 289 GDSC1; GDSC2; CTRP2 6.8809 15.5244 1.9822 15.0645
HCC2279 CTRP2 6.9094 12.4596 3.526 8.9976
NCI-H1385 CTRP2 6.9114 15.6522 1.9425 15.1541
LC-1/sq-SF CTRP2; CCLE 6.9391 16.6575 1.4638 16.7975
NCI-H226 GDSC1; GDSC2; CTRP2; CCLE 6.9432 8.9523 5.2538 1.9364
SBC-5 GDSC2; CTRP2; CCLE 6.9605 8.2383 5.584 0.7287
HCC1588 CTRP2 6.9898 13.3146 3.164 10.3258
SW1573 GDSC2; CTRP2; CCLE 6.9913 13.0998 3.2714 9.8916
DMS 273 GDSC2; CTRP2 7.0004 10.867 4.3759 5.3678
HCC1833 CTRP2 7.0065 10.3173 4.6469 4.2561
NCI-H2106 CTRP2 7.0091 10.8733 4.3791 5.3415
NCI-H23 GDSC1; GDSC2; CTRP2; CCLE 7.0229 10.1133 4.7563 3.7915
NCI-H520 GDSC2; CTRP2; CCLE 7.0363 9.5059 5.054 2.5924
NCI-H838 GDSC2; CTRP2 7.0947 10.5565 4.5923 4.3491
NCI-H1299 GDSC2; CTRP2; CCLE 7.149 12.9469 3.4649 8.8491
COLO 668 GDSC1; GDSC2; CTRP2 7.151 9.0573 5.3296 1.4236
HCC366 GDSC2; CTRP2 7.1571 13.7254 3.0872 10.3505
HCC78 GDSC2; CTRP2; CCLE 7.1928 10.9938 4.449 4.7855
NCI-H522 GDSC2; CTRP2; CCLE 7.2352 12.5372 3.729 7.6414
NCI-H1395 CTRP2 7.2744 11.8243 4.1043 6.0593
NCI-H441 GDSC2; CTRP2; CCLE 7.2973 13.8845 3.1132 10.0158
RERF-LC-Ad2 CTRP2 7.3295 12.1981 3.9616 6.5541
COR-L95 GDSC1; CTRP2 7.377 9.1116 5.4273 0.8924
HCC1438 CTRP2 7.3826 11.0158 4.5659 4.056
NCI-H1105 GDSC2; CTRP2 7.3915 10.9856 4.586 3.9648
NCI-H2087 GDSC2; CTRP2; CCLE 7.395 14.4363 2.914 10.6408
ChaGo-K-1 GDSC2; CTRP2 7.3968 10.8166 4.6693 3.6313
NCI-H2444 GDSC2; CTRP2; CCLE 7.4249 14.9113 2.7023 11.4139
NCI-H727 GDSC2; CTRP2; CCLE 7.5381 13.2162 3.6142 7.6379
NCI-H2342 GDSC2; CTRP2 7.5828 11.6268 4.4076 4.4143
LCLC-103H GDSC2; CTRP2; CCLE 7.604 11.3184 4.5662 3.7686
SHP-77 GDSC1; GDSC2; CTRP2; CCLE 7.6326 9.2846 5.4791 0.5719
NCI-H2172 GDSC2; CTRP2; CCLE 7.6582 12.0312 4.2655 4.8728
NCI-H2126 CTRP2 7.6985 10.5418 4.9787 2.1182
NCI-H2023 GDSC2; CTRP2; CCLE 7.711 12.5945 4.0325 5.7209
NCI-H2196 GDSC1; GDSC2; CTRP2 7.7268 9.4231 5.4668 0.5512
NCI-H810 GDSC2; CTRP2; CCLE 7.7658 9.053 5.623 0.2014
HCC1195 CTRP2 7.8784 13.2202 3.8458 6.2275
NCI-H1092 GDSC1; GDSC2; CTRP2; CCLE 8.0526 9.6961 5.5008 0.3289
NCI-H2029 GDSC2; CTRP2 8.0645 9.3861 5.6171 0.1371
T3M-10 CTRP2; CCLE 8.0687 10.3798 5.2413 0.9546
NCI-H2081 GDSC1; GDSC2; CTRP2 8.6286 10.341 5.4902 0.1851
NCI-H460 GDSC2; CTRP2; CCLE 11.8414 24.5194 1.0748 10.9637
MOR/CPR CTRP2; CCLE 12.0472 24.6279 1.1511 10.502
BEN GDSC2; CTRP2 12.8515 34.3769 -2.9289 19.7419
Hs 888.Lu CTRP2 5.5431 9.2557 4.0039 9.5941
⏷ Show the Full List of 226 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 3.1559 5.3477 0.2527 1.0914
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 3.0169 9.8098 1.2847 26.3149
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 5.1974 8.4172 4.0948 9.9901
Aska-SS CTRP2 6.4315 9.2394 4.7569 4.7091
TE 617.T CTRP2; CCLE 1.3357 3.676 1.3104 31.4544
Hs 633.T GDSC2 2.3791 4.9122 0.0386 3.0556
SW684 GDSC1; GDSC2 2.3913 3.792 0.5232 0.6834
EW-8 GDSC1; GDSC2 2.462 4.6067 0.2199 1.9769
SW872 GDSC1; GDSC2 2.5525 4.1304 0.462 0.7852
VA-ES-BJ GDSC1; GDSC2 2.5682 4.7615 0.2094 1.8915
MFH-ino GDSC1; GDSC2 3.5424 5.7782 0.2537 0.8067
STS-0421 GDSC2 3.797 5.8699 2.4189 4.4753
Rh41 GDSC2; CTRP2 4.2091 7.781 3.3982 15.2582
BT-16 CTRP2 4.3989 8.6701 3.1948 15.5714
MES-SA GDSC2; CCLE 4.4863 6.6863 2.1985 1.7092
TE 441.T GDSC1; GDSC2; CTRP2 4.5849 7.4472 3.9307 12.173
A-204 GDSC2; CTRP2; CCLE 4.7536 10.8855 2.4789 17.5439
Rh30 GDSC2; CCLE 4.807 8.2618 1.6789 3.6154
GCT GDSC2; CTRP2; CCLE 4.8593 9.3162 3.3399 13.8682
SW982 GDSC2; CTRP2 5.5344 8.9093 4.1675 8.9315
SK-LMS-1 GDSC1; GDSC2; CTRP2; CCLE 5.742 9.2953 4.1606 8.5209
Rh18 CTRP2 5.902 10.5378 3.6779 10.2131
G-401 GDSC2; CTRP2; CCLE 6.3603 10.4158 4.1161 7.513
TTC-709 CTRP2 6.4304 9.9902 4.3832 6.2714
G-402 GDSC2; CTRP2; CCLE 6.4314 9.7027 4.5269 5.6694
HT-1080 GDSC2; CTRP2; CCLE 6.4896 10.1821 4.3339 6.374
Tm87-16 CTRP2 6.7653 9.7588 4.7483 4.204
KYM-1 GDSC2; CTRP2; CCLE 6.9139 9.787 4.8388 3.6147
BT-12 CTRP2 7.0311 10.451 4.5993 4.413
Hs 729.T CTRP2; CCLE 7.4992 11.6 4.3654 4.6921
RD GDSC2; CTRP2; CCLE 7.6636 11.7632 4.3955 4.3559
SK-UT-1 GDSC1; GDSC2; CTRP2 8.3748 11.346 4.9915 1.4794
RKN GDSC2; CTRP2; CCLE 8.3881 13.2292 4.1665 4.3467
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 5.8865 9.4795 4.1936 8.0885
SNU-119 CTRP2 2.2597 6.3565 1.8248 26.7169
IGROV-1 GDSC2; CTRP2; CCLE 2.541 9.0252 1.1352 28.181
Caov-4 GDSC2 2.5918 10.0076 -2.2559 15.3365
JHOS-4 GDSC2; CCLE 2.9375 8.7964 0.2581 16.8228
OVCAR-3 GDSC2; CCLE 3.0678 8.7427 0.1849 14.4775
COV504 CCLE 3.543 7.6099 1.1305 8.8351
JHOC-5 CTRP2 3.5994 10.3788 1.6101 23.6181
OC 316 CCLE 3.8015 6.3604 1.9318 4.0714
OC 315 CCLE 3.8153 5.7994 2.2074 2.6396
OVMANA CCLE 4.0146 6.9243 1.8054 4.3405
COV434 CTRP2 4.085 9.581 2.4614 19.2347
ES-2 GDSC1; GDSC2; CCLE 4.1752 6.7455 1.9925 3.0506
ONCO-DG-1 CTRP2; CCLE 4.2506 12.8405 1.056 23.8365
SNU-8 CTRP2 4.3573 13.1911 0.9832 23.8141
OVTOKO GDSC2; CTRP2; CCLE 4.4236 10.7401 2.239 19.2444
SNU-840 CTRP2 4.5052 14.1633 0.6403 24.536
FU-OV-1 GDSC2; CTRP2; CCLE 4.5855 10.1396 2.6825 17.1451
COV318 CCLE 4.6466 5.9808 2.5593 0.3354
SK-OV-3 GDSC2; CTRP2; CCLE 4.7772 9.4968 3.1746 14.7301
A2780 GDSC2; CTRP2; CCLE 4.8292 9.1077 3.4111 13.6506
OV7 CTRP2 4.9893 7.5782 4.2857 9.7175
OAW28 GDSC2; CTRP2 5.0304 10.576 2.8865 15.3043
RMG-I GDSC2; CTRP2 5.3501 17.0692 -0.0568 24.6708
OVCAR-5 GDSC2; CTRP2 5.3532 13.6482 1.6521 19.2809
OVKATE GDSC2 5.5258 18.5218 -4.3368 17.7622
Caov-3 GDSC2; CTRP2 5.5437 11.281 2.998 13.7385
HEY A8 CTRP2; CCLE 5.556 10.4365 3.4292 11.9517
EFO-27 GDSC2; CTRP2; CCLE 5.7194 13.9503 1.8175 17.9144
OC 314 GDSC2; CTRP2; CCLE 5.8558 11.5122 3.1518 12.4737
MCAS CTRP2; CCLE 6.2238 14.7961 1.8171 16.901
OVK18 GDSC2; CTRP2 6.3899 9.4529 4.6188 5.3577
TOV-21G GDSC2; CTRP2; CCLE 6.459 10.3165 4.2432 6.8059
TYK-nu GDSC2; CTRP2; CCLE 6.7415 13.2009 3.0292 11.2973
DOV13 GDSC2; CTRP2; CCLE 6.7518 11.0044 4.1264 6.7916
OV56 GDSC2; CTRP2 6.7556 8.0604 5.5493 1.0439
OVSAHO CTRP2; CCLE 6.7596 11.0895 4.0902 6.9282
Kuramochi GDSC1; GDSC2; CTRP2; CCLE 6.8163 12.0283 3.6689 8.5705
OV-90 GDSC2; CTRP2; CCLE 6.863 8.8205 5.2648 1.9926
JHOS-2 GDSC2; CTRP2; CCLE 7.0707 11.9422 3.901 7.2009
COV362 CTRP2 7.2427 10.5255 4.7066 3.6871
JHOM-1 CTRP2 7.4378 11.1152 4.555 4.0258
COV644 CTRP2 7.7341 17.1866 1.8111 14.2021
EFO-21 GDSC2; CTRP2; CCLE 7.8294 11.0237 4.838 2.4881
OAW42 GDSC2; CTRP2 8.014 16.3642 2.4197 11.5403
TOV-112D GDSC2; CTRP2; CCLE 8.1802 21.4395 0.0463 19.0984
ES2 CTRP2 8.6444 17.0435 2.5318 10.1834
OVISE GDSC2; CTRP2 11.6292 28.8926 -1.1273 17.2432
OVCAR-8 GDSC2; CTRP2; CCLE 12.4527 26.9939 0.3067 12.4921
OVCAR-4 GDSC1; GDSC2; CTRP2; CCLE 13.2416 28.1797 0.2445 11.7942
⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 6.2565 8.4769 5 3.9972
H-STS CTRP2 6.5447 7.9688 5.4604 1.6404
P-STS CTRP2 7.8185 9.221 5.5824 0.2562
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1; GDSC2; CTRP2; CCLE 3.3871 7.6519 2.5888 20.6119
IST-Mes2 CCLE 3.4324 5.6764 2.0028 4.418
NCI-H2052 GDSC2; CTRP2; CCLE 4.0349 8.4462 2.9285 17.5539
NCI-H2452 GDSC2; CTRP2; CCLE 5.7773 9.7353 3.9719 9.2376
NCI-H28 GDSC2; CTRP2; CCLE 5.9049 11.4671 3.2159 12.1136
MPP 89 GDSC1; GDSC2; CTRP2; CCLE 7.4665 13.2249 3.5592 7.967
IST-Mes1 GDSC1; GDSC2; CTRP2; CCLE 7.4926 12.693 3.836 6.8169
ACC-MESO-1 CTRP2 8.2304 14.0599 3.6793 6.4021
JL-1 CTRP2 9.5229 35.5651 -5.9267 28.9305
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PC-3 GDSC2; CCLE 3.7299 7.5756 1.2883 7.3946
LNCaP clone FGC GDSC1; GDSC2; CTRP2 5.2383 8.9989 3.8514 10.8989
22Rv1 GDSC2; CTRP2; CCLE 6.7127 10.2266 4.4808 5.3891
PaCa-3 CTRP2 7.019 9.1924 5.1895 2.0906
NCI-H660 GDSC2; CTRP2 7.2009 14.298 2.8373 11.2627
DU145 GDSC2; CTRP2; CCLE 7.686 14.7193 2.9873 9.8897
VCaP GDSC1; GDSC2; CTRP2 8.3328 9.8289 5.5607 0.1547
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 0.8314 5.8238 0.414 35.9824
A-253 GDSC1; GDSC2; CCLE 3.9294 11.7791 -0.6411 16.2667
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 2.8093 5.1451 1.9545 9.9172
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-GT-2 GDSC2 -1.0775 0.9601 -1.2565 21.7875
NCC-StC-K140 CTRP2 -0.5383 11.5636 -3.1452 46.3651
NUGC-4 GDSC2; CTRP2; CCLE 0.2369 6.4501 -0.4087 40.2499
SNU-216 CTRP2 1.8343 8.2214 0.7145 31.6695
NCI-N87 GDSC2; CTRP2; CCLE 1.881 3.5994 1.8734 27.7628
NUGC-3 GDSC2; CTRP2; CCLE 1.8885 11.4894 -0.6129 34.8642
AZ-521 CCLE 1.9208 5.368 0.8292 14.7391
TGBC11TKB GDSC2 2.2701 7.6613 -1.3407 11.2585
MKN28 GDSC2 2.7081 7.6047 -1.0103 8.416
HSC-39 GDSC1; GDSC2 2.8185 4.239 0.5327 0.3783
RF-48 GDSC1; GDSC2 2.9487 5.8657 -0.065 2.7607
ECC10 GDSC2; CTRP2 3.1849 6.9297 2.6439 20.9858
SCH GDSC1; GDSC2 3.3743 6.0443 2.0041 7.9073
SNU-16 GDSC1; GDSC2; CTRP2; CCLE 3.8142 6.6201 3.4321 16.2251
GCIY GDSC1; GDSC2; CCLE 3.8289 14.581 -2.1151 22.1419
TMK-1 GDSC2 3.8398 8.1697 1.3149 11.1827
BGC-823 CCLE 3.8554 6.9418 1.6884 5.2382
KE-39 CTRP2; CCLE 3.8578 11.7431 1.2167 24.2868
GSS CTRP2 3.8743 6.6833 3.4752 15.8898
KATO III GDSC2; CTRP2 3.9382 8.0753 2.9914 17.5648
RERF-GC-1B GDSC2; CCLE 3.9506 9.2638 0.6207 10.3277
HGC-27 GDSC2; CTRP2; CCLE 4.4241 10.4511 2.3787 18.7114
SNU-1 GDSC1; GDSC2; CTRP2; CCLE 4.8318 9.0443 3.4438 13.5114
SNU-601 CTRP2 4.841 11.467 2.2748 18.1265
Fu97 GDSC2; CTRP2; CCLE 5.2729 8.4183 4.166 9.5219
Hs 746.T GDSC2; CTRP2; CCLE 6.101 9.8481 4.1895 7.6863
23132/87 GDSC2; CTRP2 6.1042 15.6885 1.2721 19.0409
MKN74 CTRP2; CCLE 6.1162 12.669 2.7917 13.4081
SNU-620 CTRP2 6.1742 8.5026 4.9218 4.4741
MKN1 GDSC2; CTRP2 6.2995 11.8652 3.3438 10.8278
SNU-5 GDSC1; GDSC2; CTRP2 6.3572 9.7309 4.4549 6.1008
GSU CTRP2 6.4796 10.1054 4.3642 6.265
IM95 GDSC2; CTRP2; CCLE 6.9821 15.6094 2.0191 14.7476
LMSU CTRP2 7.1553 10.5343 4.6442 4.0548
MKN45 GDSC2; CTRP2; CCLE 7.1793 8.3971 5.6256 0.4481
ECC12 GDSC1; GDSC2; CTRP2 7.2536 12.4372 3.7911 7.3608
HuG1-N CTRP2 7.7309 11.2368 4.6828 3.1703
SNU-719 CTRP2 7.8728 13.419 3.7471 6.6238
MKN7 GDSC2; CTRP2; CCLE 7.9586 15.41 2.8451 10.019
SNU-668 CTRP2 7.9896 14.0211 3.5376 7.2834
AGS GDSC2; CTRP2 8.0304 13.9669 3.591 7.017
OCUM-1 GDSC2; CTRP2; CCLE 8.192 9.8388 5.5038 0.2766
SH-10-TC CTRP2; CCLE 9.2218 17.3949 2.7484 8.6019
SNG-M GDSC2; CTRP2; CCLE 3.5231 6.8385 3.0414 18.5269
SNU-1077 CTRP2 6.0376 9.7529 4.1845 7.8293
SNU-685 CTRP2 7.2506 10.6048 4.6741 3.8053
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HTC-C3 GDSC2 1.9267 5.2792 -0.4251 6.6464
WRO GDSC2 2.1879 4.57 0.081 3.1373
IHH-4 GDSC2 2.3867 3.8024 0.517 0.7108
ASH-3 GDSC2 2.5974 4.2445 0.4372 0.844
K5 GDSC1; GDSC2 3.8929 5.4578 0.5002 0.122
8305C GDSC2; CTRP2; CCLE 3.9612 7.6919 3.1776 16.7817
TT GDSC2; CTRP2 4.214 12.4487 1.2129 23.4106
KMH-2 GDSC2 4.5685 7.1181 2.3347 3.4207
ML-1 [Human leukemia] GDSC2; CTRP2 5.0926 8.6463 3.8847 11.0975
B-CPAP GDSC2; CTRP2; CCLE 5.1493 10.4895 3.038 14.4291
SW579 CTRP2; CCLE 5.8502 9.1546 4.3247 7.6118
CAL-62 GDSC2; CTRP2 6.0454 9.726 4.2044 7.7306
CGTH-W-1 GDSC1; GDSC2; CTRP2 6.4564 10.7719 4.0146 7.7641
FTC-238 CTRP2 6.5246 9.6827 4.6083 5.1705
TT2609-C02 GDSC2; CTRP2; CCLE 6.6955 10.5545 4.3063 6.1397
FTC-133 GDSC2; CTRP2 6.9898 10.0776 4.7509 3.8601
8505C GDSC2; CTRP2; CCLE 8.0158 14.414 3.3668 7.914
BHT-101 GDSC2; CTRP2 8.3523 16.1385 2.7672 9.7291
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-10B CTRP2 -3.8032 5.0427 -4.4465 61.2681
DOK GDSC2 -2.3078 4.3043 -3.8443 38.7406
BB30-HNC GDSC1; GDSC2 -1.6003 3.3732 -2.0639 48.1166
SNU-1076 CTRP2 -1.3405 5.222 -1.8062 49.3192
Ca9-22 GDSC2 -0.3228 5.0654 -2.2184 23.8646
NCI-H3118 GDSC2 -0.1286 7.6103 -3.2871 27.849
SAT [Human HNSCC] GDSC2 0.2286 4.449 -1.4031 17.4566
JHU-029 GDSC2 0.2788 4.5827 -0.4122 33.7435
BHY GDSC2; CTRP2 0.4054 5.3263 0.0706 38.4992
UPCI-SCC-090 GDSC2 0.661 6.6761 -2.1253 19.9915
BICR 56 CTRP2 0.6691 9.9894 -1.226 40.0483
JHU-022 GDSC2 0.6827 9.8421 -3.6882 26.6761
PCI-15A GDSC2 0.7349 6.2963 -0.6373 32.4273
CAL-27 GDSC2; CTRP2; CCLE 0.7853 6.4291 0.1955 36.7339
HO-1-u-1 GDSC2 0.9419 7.1215 -2.1093 19.035
SNU-1214 CTRP2 0.9613 6.1908 0.4564 35.3924
JHU-011 GDSC2 1.396 9.4819 -1.4805 32.5731
PE/CA-PJ34 (clone C12) CTRP2 1.3978 6.2542 0.9146 32.5189
SAS GDSC2 1.4965 5.1323 -0.6684 9.175
HO-1-N-1 GDSC2 1.5808 4.7411 -0.4114 7.3736
SCC-25 GDSC2; CTRP2 1.8246 5.6298 1.5455 29.0573
PCI-06A GDSC2 1.8738 9.4866 -1.0372 29.2644
HSC-2 GDSC2; CTRP2; CCLE 2 7.9271 1.0041 30.2603
OSC-20 GDSC2 2.0133 5.6124 -0.5261 7.0635
BICR 78 GDSC2 2.0395 9.3 -2.3187 17.0115
KON GDSC2 2.2323 12.1129 -2.0116 31.2058
SCC-15 GDSC1; GDSC2 2.3299 7.4699 -1.2048 10.3477
PCI-30 GDSC2 2.3951 9.2686 -2.0371 14.7131
CAL-33 GDSC2; CTRP2 2.5232 8.7153 1.2461 27.8751
PCI-04B GDSC2 2.599 9.896 -0.5855 24.9247
KOSC-2 GDSC2 2.6166 9.2245 -0.2359 23.307
SKN-3 GDSC2 2.6792 10.2569 -2.3146 15.4162
BICR 10 GDSC2 2.8659 12.3856 -3.2225 19.0297
HSC-3 GDSC2; CTRP2 3.0689 12.4233 0.1301 29.638
SNU-1041 CTRP2 3.551 10.2517 1.621 23.7085
Hs 840.T CCLE 3.6027 6.6816 1.6342 6.0276
SNU-1066 CTRP2 3.7024 10.9171 1.4593 23.8697
HSC-4 GDSC2; CTRP2 3.8251 14.6584 -0.2278 28.6191
OSC-19 GDSC2 3.8381 8.2602 1.2687 11.4645
SCC-9 GDSC2; CTRP2; CCLE 3.899 10.8221 1.6956 22.5394
BB49-HNC GDSC1; GDSC2 3.8993 6.256 0.2212 0.6979
PE/CA-PJ49 CTRP2 3.9083 10.7623 1.733 22.383
LB771-HNC GDSC1; GDSC2 4.2698 15.6328 -3.8031 18.2495
BICR 22 GDSC2; CTRP2 4.3901 12.2854 1.4569 22.1577
SNU-899 CTRP2 4.4551 8.9663 3.1134 15.7554
PE/CA-PJ15 GDSC2; CTRP2 4.4709 12.3259 1.5122 21.7731
BICR 31 GDSC2; CTRP2 4.5766 10.7895 2.3599 18.4181
FaDu GDSC2; CTRP2; CCLE 4.7651 14.6993 0.6094 24.0288
Detroit 562 GDSC2; CTRP2; CCLE 4.9487 12.3252 1.9498 19.0978
SNU-46 CTRP2 5.1217 9.9492 3.2782 13.5159
PE/CA-PJ41 (clone D2) CTRP2 5.3445 13.4313 1.7526 18.9409
BICR 16 CTRP2 5.9321 17.1039 0.4208 22.0936
BICR 18 CTRP2 6.4251 9.7183 4.5143 5.733
YD-8 CTRP2 6.5715 10.3753 4.301 6.3702
BICR 6 CTRP2 6.6599 22.2862 -1.5694 25.8429
SCC-4 GDSC2; CTRP2 7.9255 23.7217 -1.2797 22.9765
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-BLC1 CTRP2 -3.6585 -0.163 -3.6657 64.2955
SCaBER CTRP2; CCLE 0.8668 6.04 0.3951 35.9045
5637 GDSC2; CTRP2; CCLE 0.9015 4.8657 0.7041 34.8876
JMSU-1 CTRP2; CCLE 2.3682 5.4825 2.1707 25.1691
253J CTRP2 2.7315 6.9551 2.1449 24.1443
VM-CUB-1 CTRP2 3.6142 10.017 1.7923 22.9357
SW780 GDSC2; CCLE 3.688 9.3122 0.3973 11.9942
HT-1376 GDSC2; CTRP2; CCLE 3.7051 12.1096 0.8946 25.7176
CAL-29 GDSC2; CTRP2 3.7586 11.2324 1.3647 24.0459
253J-BV CTRP2 3.9679 10.4981 1.9161 21.5722
RT-4 GDSC2; CTRP2; CCLE 5.1191 10.2809 3.1129 14.1936
UM-UC-3 GDSC2; CTRP2; CCLE 5.4005 7.9227 4.5265 7.7426
T24 GDSC2; CTRP2; CCLE 5.5674 9.98 3.6662 10.947
BC-3C CTRP2 5.6967 11.8701 2.837 14.0672
RT-112 GDSC2; CTRP2; CCLE 5.72 10.0049 3.7877 10.1241
BFTC-905 GDSC2; CTRP2 5.9644 8.3614 4.8186 5.3089
KMBC-2 CTRP2; CCLE 6.0427 18.5418 -0.2057 23.658
SW1710 GDSC2; CTRP2 6.5295 15.097 1.9158 15.9564
TCCSUP GDSC2; CTRP2; CCLE 7.3417 13.5065 3.3315 9.0742
HT-1197 GDSC2; CTRP2; CCLE 7.8393 12.9985 3.9255 5.9674
KU-19-19 GDSC2; CTRP2 8.5645 21.9606 0.0765 18.3923
J82 GDSC2; CTRP2; CCLE 9.21 16.8685 2.9882 7.7412
639V GDSC2; CTRP2; CCLE 9.8294 18.7034 2.5225 8.639
647V GDSC2; CTRP2 10.3905 24.0031 0.3779 14.8447
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVCA420 GDSC2 -1.799 3.8027 -3.102 33.9582
CAL-39 GDSC2 -1.0797 3.7479 -2.3418 27.4992
OVMIU GDSC2 0.0291 6.2866 -2.4904 23.9044
BPH-1 GDSC2 0.0509 9.559 -4.094 30.0274
DSH1 GDSC1; GDSC2 1.4525 3.2234 0.2392 3.6499
NCC-IT GDSC1; GDSC2 1.8138 4.3613 -0.0603 4.6826
DoTc2 4510 GDSC2 2.0014 5.9208 -0.684 8.0412
PA-1 GDSC2 2.0842 7.4145 -1.3546 11.7821
C-33 A GDSC2 2.128 7.2658 -1.2498 11.0776
TC-YIK GDSC2 2.1469 6.052 -0.6459 7.4866
C-4-I GDSC2 2.2294 11.5855 -3.3063 20.9167
SiHa GDSC2 2.3983 3.4073 0.6709 0.2143
HEC-1 GDSC2 2.4012 4.065 0.4179 1.109
UWB1.289 GDSC2 2.4298 7.5768 0.4119 20.7101
NEC8 GDSC1; GDSC2 2.4522 4.0903 0.4319 0.9972
HT-3 GDSC2 2.4534 6.0865 -0.458 5.7454
PEO1 GDSC2 2.4598 6.8354 -0.8091 7.7765
LB831-BLC GDSC1; GDSC2 2.6522 6.6027 -0.5733 6.0291
HEY GDSC2 2.6828 9.8584 -2.1171 14.4351
PWR-1E GDSC2 2.7425 7.3636 -0.8732 7.5669
ME-180 GDSC2 2.763 13.3498 -3.7742 21.4096
NT2-D1 GDSC1; GDSC2 2.7964 5.5302 -0.0012 2.6448
SiSo GDSC2 2.8786 8.8374 -1.4852 10.6954
SKG-IIIa GDSC2 2.9274 4.9342 0.3132 1.0485
SW954 GDSC1; GDSC2 3.1344 9.2306 0.2099 18.8676
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 3.1592 5.1153 2.2863 6.8025
MS751 GDSC2 3.1809 11.8262 -2.7209 16.1613
KGN GDSC1; GDSC2 3.582 10.4838 -1.8014 10.9094
Ca Ski GDSC2 3.6284 12.4037 -2.6879 15.0473
SKN GDSC2 3.8111 6.4185 0.1232 1.0651
OVCA433 GDSC2 3.9106 7.3633 1.7684 8.2325
JAR GDSC1; GDSC2 3.9273 6.8229 2.0468 6.2476
ACC-OV7 GDSC2 3.9932 7.3037 1.859 7.4708
SW756 GDSC2 4.5945 14.1248 -2.8629 13.8995
OV17R GDSC2 4.9912 10.0501 1.2268 8.9781
JHOS-3 GDSC2 5.0677 9.7203 1.4344 7.6419
JEG-3 GDSC2 5.3181 6.9745 2.7732 0.5175
SW962 GDSC1; GDSC2 6.1648 19.9495 -2.758 22.8736
HeLa GDSC2; CTRP2 14.2961 38.3513 -3.8577 19.8996
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Erlotinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Erlotinib and Porfimer Sodium. Lung cancer [2C25] [13]
Ceritinib DMB920Z Moderate Decreased metabolism of Erlotinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
PF-06463922 DMKM7EW Moderate Increased metabolism of Erlotinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [14]
Capmatinib DMYCXKL Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [15]
Coadministration of a Drug Treating the Disease Different from Erlotinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [16]
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Erlotinib due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [16]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Erlotinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Midostaurin DMI6E0R Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [17]
Arn-509 DMT81LZ Moderate Increased metabolism of Erlotinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Mitotane DMU1GX0 Moderate Increased metabolism of Erlotinib caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [14]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [18]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Erlotinib caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [14]
Voriconazole DMAOL2S Moderate Decreased metabolism of Erlotinib caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Posaconazole DMUL5EW Moderate Decreased metabolism of Erlotinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Ciprofloxacin XR DM2NLS9 Moderate Decreased metabolism of Erlotinib caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [19]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Erlotinib caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Rabeprazole DMMZXIW Major Decreased absorption of Erlotinib due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [16]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Erlotinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Erlotinib caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Erdafitinib DMI782S Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [20]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Erlotinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [21]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Erlotinib caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Decreased metabolism of Erlotinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
PF-04449913 DMSB068 Moderate Decreased clearance of Erlotinib due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [17]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Erlotinib caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [14]
Anisindione DM2C48U Moderate Increased plasma concentration of Erlotinib and Anisindione due to competitive binding of plasma proteins. Coagulation defect [3B10] [19]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Erlotinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [14]
Ivacaftor DMZC1HS Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [23]
MK-8228 DMOB58Q Moderate Decreased metabolism of Erlotinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [24]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Erlotinib caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [14]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Erlotinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [16]
Primidone DM0WX6I Moderate Increased metabolism of Erlotinib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Felbamate DM1V5ZS Moderate Increased metabolism of Erlotinib caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Erlotinib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Cenobamate DM8KLU9 Moderate Increased metabolism of Erlotinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Stiripentol DMMSDOY Moderate Decreased metabolism of Erlotinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Erlotinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Phenobarbital DMXZOCG Moderate Increased metabolism of Erlotinib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Carbamazepine DMZOLBI Moderate Increased metabolism of Erlotinib caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Erlotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [14]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Cannabidiol. Epileptic encephalopathy [8A62] [17]
Tazemetostat DMWP1BH Moderate Increased metabolism of Erlotinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [14]
Itraconazole DMCR1MV Moderate Decreased metabolism of Erlotinib caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Miconazole DMPMYE8 Moderate Decreased metabolism of Erlotinib caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Erlotinib caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Dexlansoprazole DM1DBV5 Major Decreased absorption of Erlotinib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [16]
Nizatidine DMGFV3Z Moderate Decreased absorption of Erlotinib due to altered gastric pH caused by Nizatidine. Gastro-oesophageal reflux disease [DA22] [16]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Erlotinib caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [14]
Boceprevir DMBSHMF Moderate Decreased metabolism of Erlotinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Telaprevir DMMRV29 Moderate Decreased metabolism of Erlotinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
GS-5885 DMSL3DX Moderate Decreased clearance of Erlotinib due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [25]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Erlotinib caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [19]
Rifampin DMA8J1G Moderate Increased metabolism of Erlotinib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [14]
Rifapentine DMCHV4I Moderate Increased metabolism of Erlotinib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [14]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [26]
Delavirdine DM3NF5G Moderate Decreased metabolism of Erlotinib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Erlotinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Erlotinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Efavirenz DMC0GSJ Moderate Increased metabolism of Erlotinib caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Saquinavir DMG814N Moderate Decreased metabolism of Erlotinib caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Etravirine DMGV8QU Moderate Increased metabolism of Erlotinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Erlotinib caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Darunavir DMN3GCH Moderate Decreased metabolism of Erlotinib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Atazanavir DMSYRBX Moderate Decreased metabolism of Erlotinib caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Erlotinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [28]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Erlotinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [29]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Erlotinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [30]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Erlotinib due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [17]
Verapamil DMA7PEW Moderate Decreased metabolism of Erlotinib caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [19]
Conivaptan DM1V329 Moderate Decreased metabolism of Erlotinib caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [14]
Tolvaptan DMIWFRL Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [16]
Amobarbital DM0GQ8N Moderate Increased metabolism of Erlotinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [14]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Methotrexate. Leukaemia [2A60-2B33] [17]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [31]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Idelalisib. Mature B-cell leukaemia [2A82] [32]
IPI-145 DMWA24P Moderate Decreased metabolism of Erlotinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [33]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Clofarabine. Mature B-cell lymphoma [2A85] [34]
Ibrutinib DMHZCPO Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Ibrutinib. Mature B-cell lymphoma [2A85] [17]
Vemurafenib DM62UG5 Moderate Increased metabolism of Erlotinib caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [14]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Erlotinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [14]
Lasmiditan DMXLVDT Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [35]
Exjade DMHPRWG Moderate Increased metabolism of Erlotinib caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [14]
Rifabutin DM1YBHK Moderate Increased metabolism of Erlotinib caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [14]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Erlotinib and Methoxsalen. Mycosis fungoides [2B01] [16]
Nilotinib DM7HXWT Moderate Decreased metabolism of Erlotinib caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [36]
Dasatinib DMJV2EK Moderate Decreased metabolism of Erlotinib caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Erlotinib and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [38]
Modafinil DMYILBE Minor Increased metabolism of Erlotinib caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [39]
Rolapitant DM8XP26 Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [40]
Abametapir DM2RX0I Moderate Decreased metabolism of Erlotinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [41]
Ranitidine DM0GUSX Moderate Decreased absorption of Erlotinib due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [16]
Esomeprazole DM7BN0X Major Decreased absorption of Erlotinib due to altered gastric pH caused by Esomeprazole. Peptic ulcer [DA61] [16]
Famotidine DMRL3AB Moderate Decreased absorption of Erlotinib due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [16]
Lefamulin DME6G97 Moderate Decreased metabolism of Erlotinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [42]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Erlotinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [14]
Enzalutamide DMGL19D Moderate Increased metabolism of Erlotinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Bosentan DMIOGBU Moderate Increased metabolism of Erlotinib caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [14]
Riociguat DMXBLMP Moderate Decreased metabolism of Erlotinib caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [29]
Dexamethasone DMMWZET Moderate Increased metabolism of Erlotinib caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [14]
Nafcillin DMN9RPO Moderate Increased metabolism of Erlotinib caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [14]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Erlotinib and Leflunomide. Rheumatoid arthritis [FA20] [29]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Erlotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [17]
Larotrectinib DM26CQR Moderate Decreased metabolism of Erlotinib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [17]
Armodafinil DMGB035 Minor Increased metabolism of Erlotinib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [39]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Erlotinib and Naltrexone. Substance abuse [6C40] [43]
Warfarin DMJYCVW Moderate Increased plasma concentrations of Erlotinib and Warfarin due to competitive inhibition of the same metabolic pathway. Supraventricular tachyarrhythmia [BC81] [19]
Fostamatinib DM6AUHV Moderate Decreased clearance of Erlotinib due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [44]
Elagolix DMB2C0E Moderate Increased metabolism of Erlotinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [14]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Erlotinib caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [19]
⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Erlotinib 25 mg tablet 25 mg Oral Tablet Oral
Erlotinib 100 mg tablet 100 mg Oral Tablet Oral
Erlotinib 150 mg tablet 150 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Erlotinib FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
8 Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
9 Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
10 In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
11 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
12 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
13 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
14 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
15 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19 Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
20 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
21 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
22 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
23 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
24 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
25 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
26 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
27 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
28 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
29 Canadian Pharmacists Association.
30 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
31 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
32 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
33 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
34 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
35 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
36 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
38 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
39 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
40 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
41 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
42 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
43 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
44 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.